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Background: Tuberculosis (TB) is the most common opportunistic infection in children 
with human immunodeficiency virus (HIV) infection in developing countries, and 
co-treatment for HIV infection and TB is frequently indicated. Efavirenz and 
lopinavir/ritonavir (ratio 1:1) as part of antiretroviral therapy are used in combination 
with rifampicin-based antitubercular treatment in South African TB/HIV co-infected 
children. Adult studies show that concomitant rifampicin significantly reduces efavirenz 
and lopinavir plasma concentrations. However, the pharmacokinetics (PK) of efavirenz 
and lopinavir/ritonavir are poorly characterized in children, especially African children 
and no study has evaluated the effect of rifampicin-based antitubercular treatment on 
efavirenz and lopinavir/ritonavir plasma concentrations in children. Although therapeutic 
drug monitoring (TDM) is recommended in selected patients (including young children 
and patients receiving concomitant antitubercular treatment), TDM is seldom available in 
resource-constrained countries. There is an urgent need to develop a field friendly method 
which requires small volumes of blood, and inexpensive processing and storage 
conditions. Furthermore, because HIV replicates in the cells, efavirenz and lopinavir need 
to penetrate into these infected cells to inhibit viral replication. Therefore, directly 
measurement of intracellular concentrations of these drugs in HIV-infected children 
could provide better understanding of drug exposure at the action site. It is also important 
to evaluate the effects of frequently co-administered drugs on intracellular accumulation 
of efavirenz and lopinavir. 
 
Objectives: 1) To evaluate efavirenz and lopinavir/ritonavir plasma concentrations and 
determine the effects of rifampicin on efavirenz and lopinavir/ritonavir PK in 
HIV-infected African children with and without rifampicin-based antitubercular 
treatment. 2) To develop and validate the dried blood spot (DBS) method as an 
alternative to conventional plasma methods of drug concentration measurement in TDM. 
3) To evaluate in vivo intracellular concentrations of efavirenz and lopinavir/ritonavir in 
HIV-infected children with and without concomitant antitubercular treatment. 4) To 











and lopinavir in human peripheral blood mononuclear cells (PBMCs) by drug efflux 
protein inhibitors, as well as frequently co-administered rifampicin and ritonavir (at low 
dose; as pharmacoenhancer). 
 
Methods: 1) Plasma efavirenz and lopinavir/ritonavir concentrations were measured by 
validated liquid chromatography/tandem mass spectrometry (LC/MS/MS) method  in 
TB/HIV co-infected children during and after rifampicin-based antitubercular treatment 
as well as in a group of controls (HIV-infected children without TB). Children in the 
efavirenz study (n= 30) were receiving standard doses of efavirenz as part of 
antiretroviral treatment. Trough concentrations (Cmin) of efavirenz were estimated by 
extrapolation of the log-linear concentration-time line to 24 hours after the previous dose. 
Children in the lopinavir/ritonavir study were receiving additional ritonavir (lopinavir: 
ritonavir ratio 1:1) during antitubercular treatment (n= 15), and standard doses of 
lopinavir/ritonavir (LPV/r; ratio 4:1) after antitubercular treatment, and in controls (n= 
15). The PK of lopinavir and ritonavir were characterized from concentration-time curves 
using WinNonlin version 4.1 by non-compartmental analysis. 
 
2) Aliquots of 50 µL of whole blood from the efavirenz and lopinavir/ritonavir studies 
were dried onto filter paper. The drug concentrations were analyzed using validated 
LC/MS/MS method. The effects of high temperature and direct sunlight on the stabilities 
of these antiretroviral drugs in DBS samples were tested. 
 
3) Intracellular concentrations of efavirenz, lopinavir and ritonavir were measured in 
trough concentrations of 11 TB/HIV co-infected children using a validated LC/MS/MS 
method. Six children were receiving double dose of LPV/r (4:1) with concomitant 
rifampicin; 5 children were receiving standard doses of efavirenz with rifampicin-based 
antitubercular treatment, 3 of them had intracellular concentrations measured again after 
completing rifampicin-based antitubercular treatment. 
 
4) in vitro intracellular accumulation of efavirenz and lopinavir were measured in human 











furosemide at 50 µM and cyclosporine A at 20 µM) and frequently co-administered drugs 
at levels representing the average concentrations found in patients (ritonavir at 5 mg/L 
and rifampicin at 4 mg/L). The concentrations of efavirenz and lopinavir in PBMCs were 
determined by LC/MS/MS. 
 
Results and Conclusions: 1) The co-administration of rifampicin did not significantly 
reduce efavirenz estimated Cmin concentrations. A high proportion of children with and 
without concomitant antitubercular treatment had sub-therapeutic efavirenz 
concentrations despite being correctly dosed according to the manufacturer’s instructions, 
raising concerns about the adequacy of current efavirenz dosing recommendations in 
children. The lopinavir key PK parameter, Cmin, was not significantly different in same 
group of children during and after rifampicin-based antitubercular treatment or compared 
to HIV-infected children without tuberculosis. The recommended minimum therapeutic 
concentration was achieved in 87% of children during antitubercular treatment and in 
92% without concomitant antitubercular treatment. Therefore, in the context of limited 
options, LPV/r with additional ritonavir (ratio 1:1) is an acceptable approach to treat 
young children receiving concomitant rifampicin-based antitubercular treatment, 
although safety remains a concern and hepatic alanine transaminase levels should be 
monitored regularly. 
 
2) Plasma and DBS concentrations of efavirenz, lopinavir and ritonavir were strongly 
correlated. The median (interquartile range, IQR) DBS/plasma concentration ratios for 
efavirenz, lopinavir and ritonavir were 0.93 (IQR 0.83, 1.08), 0.73 (IQR 0.61, 0.90) and 
1.05 (IQR 0.74, 1.21), respectively. PK parameters of efavirenz and ritonavir were 
closely similar between DBS and plasma; whereas lopinavir pre-dose and Cmin (at 12 
hours after lopinavir intake) concentrations were 16% lower in DBS samples. The 3 
antiretroviral drugs in DBS samples were stable at 37 °C for 7 days and with exposure to 
direct sunlight for 2 hours. DBS can be used as an alternative field-friendly method for 
efavirenz, lopinavir and ritonavir concentration monitoring. However, pre-dose and Cmin 
concentrations of lopinavir in DBS samples need to be increased by 16% when used to 












3) In vivo median intracellular/plasma concentration ratios for efavirenz, lopinavir and 
ritonavir amongst 11 TB/HIV co-infected children during antitubercular treatment were 
0.91 (IQR 0.54, 1.19), 0.22 (IQR 0.09, 0.31) and 4.17 (IQR 1.30, 7.33), respectively. Two 
children had efavirenz intracellular/plasma concentration ratios during vs. after 
antitubercular treatment: 1.00 vs. 0.61 and 0.27 vs. 0.79. 
 
4) Furosemide significantly increased efavirenz and lopinavir accumulation in healthy 
human PBMC samples by 1.2- 1.5 fold. Whereas, neither verapamil nor cyclosporin A 
had significant effects on efavirenz or lopinavir intracellular accumulation. Despite being 
an inducer of P-glycoprotein, rifampicin increased the accumulation of both efavirenz 
and lopinavir to different extents in all 3 PBMC samples. The low-dose ritonavir (at the 
concentration found in HIV-infected patients) had no effect on intracellular accumulation 
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1.1.1 HIV Prevalence 
The human immunodeficiency virus (HIV) is a retrovirus that infects cells of the human 
immune system, destroying or impairing their function. The most advanced stage of HIV 
infection is acquired immunodeficiency syndrome (AIDS). AIDS was first reported in the 
United States in 1981. Since then, it has become a global health problem affecting all 
regions, countries and communities. In 2007, there were estimated 33.2 million people 
living with HIV worldwide, two third lived in sub-Saharan Africa, a total of 22.5 million 












Chapter 1 Introduction 
 2 
Figure 1.1 A global view of prevalence of HIV infection among population aged 15- 49 
years (2007). Image taken from 
http://www.who.int/hiv/facts/global_HIV_map_2007_fullscr.jpg (Last accessed 
08/08/2009). 
 
1.1.2 Mother-to-Child Transmission 
An estimated 2.1 million children younger than 15 years are living with HIV in 2007 
worldwide. About 90% of children living with HIV are in sub-Saharan Africa [World 
Health Statistics 2008, WHO]. Although children could be infected through blood 
transfusions and infected tools, more than 90% of them acquire HIV infection via 
mother-to-child transmission (MTCT). Women in the reproductive age are 2.5 times 
more likely to be infected than men in the same age group, and the incidence of MTCT is 
on the rise [Moodley et al. 2005]. In the absence of any intervention, the rate of MTCT 
varies between 15 and 45% (5- 10% during pregnancy, 10- 20% during labour and 
delivery and 5- 20% through breastfeeding) [de Cock et al. 2000]. 
 
1.2 Opportunistic Infections and HIV-related Tuberculosis 
1.2.1 Opportunistic Infections 
In the early stages of HIV infection, a person may not have symptoms for many years but 
can still transmit the disease to others. The virus multiplies in the body and destroys the 
immune system, as the infection progresses, immune system becomes weaker, and the 
person becomes more susceptible to infections or malignancies. AIDS represents the 
terminal stage of HIV infection when patients suffer from opportunistic infections (OIs). 
Approximately 50% of HIV-infected persons will develop AIDS after 7 to 10 years of 
infection. The average survival time for a person with AIDS may be only 6 months in 
developing countries and 1 to 3 years in developed countries. 
 
1.2.2 HIV-related Tuberculosis 
Amongst the 9.27 million incident cases of tuberculosis (TB) in 2007 worldwide, an 
estimated 1.37 million (14.8%) were HIV-positive. Deaths from TB among HIV-positive 
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[Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009]. TB is 
the leading HIV-related OI in developing countries, particularly in sub-Saharan Africa. In 
South Africa, the prevalence of HIV in incident TB cases was 73%, which is the second 
highest in the world [Global tuberculosis control: epidemiology, strategy, financing: 
WHO report 2009]. There is a 7- 10% annual risk of developing TB disease among 
HIV-infected patients with latent TB infection, which is significantly higher than those in 
HIV-negative persons [Girardi et al. 2000]. Furthermore, patients with TB disease tend to 
have higher HIV viral loads and a more rapid progression of their HIV illness than 
HIV-infected patients without TB [Whalen et al. 1995]. 
 
There is an extremely high incidence (48%) of TB among HIV-infected South African 
children, especially prior to antiretroviral (ARV) treatment [Walters et al. 2008]. In the 
absence of ARV therapy, HIV-infected children with confirmed TB have poor outcomes 
on antitubercular therapy, and are at high risk of death during or after completion of 
antitubercular therapy [Hesseling et al. 2005]. Co-treatment with ARV therapy is likely 
to reduce TB related morbidity and mortality in TB/HIV co-infected children [Walters et 
al. 2008]. 
 
1.3 Treatment in HIV-infected Children with TB 
1.3.1 Combination Antiretroviral Therapy in Children 
Effective antiretroviral therapy includes at least three drugs from two different ARV 
classes among nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside 
transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). Since the introduction of 
combination antiretroviral therapy (cART), a reduction of 60- 90% in HIV-related deaths 
and OIs has been observed among adults living in the developed countries [Mocroft et al. 
1998; de Martino et al. 2000]. The effectiveness of cART in infants and children to 
reduce HIV-1-related death is similar, or even greater than, that observed in adults 
[Bolton-Moore et al. 2007]. 
 
The South African national paediatric antiretroviral treatment guidelines recommended 
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Table 1.1 Paediatric first-line and second-line treatments. Lopinavir co-formulated with 
ritonavir in a lopinavir: ritonavir ratio of 4:1 (LPV/r) as Kaletra® is used in South African 
children aged between 6 months to 3 years, who have failed nevirapine-based prevention 
of MTCT. [National Antiretroviral Treatment Guidelines, 2004] 
 
 6 months- 3 years old >3 years old or >10 Kg 
First-line 
• Stavudine -NRTIs 
• Lamivudine -NRTIs 
• Lopinavir/ritonavir -PIs 
• Stavudine -NRTIs 
• Lamivudine -NRTIs 
• Efavirenz -NNRTIs 
Second-line 
• Zidovudine -NRTIs 
• Didanosine -NRTIs 
• Nevirapine -NNRTIs 
• Zidovudine -NRTIs 
• Didanosine -NRTIs 
• Lopinavir/ritonavir -PIs 
 
1.3.2 Antitubercular Treatment in Children 
Treatment regimens for drug susceptible TB have an initial (or intensive) phase lasting 2 
months and a continuation phase usually lasting 4 months. During the intensive phase, 
treatment comprises 3 or more drugs (isoniazid, rifampicin, pyrazinamide and, in children 
with extensive disease, ethambutol), in order to rapidly kill tubercle bacilli. During the 
continuation phase, treatment consists of fewer drugs (isoniazid and rifampicin) but lasts 
for a longer time. The sterilizing effect of the drugs eliminates the remaining bacilli and 
prevents subsequent relapse. Antitubercular treatment is the same for HIV infected and 
HIV negative children with TB. [South African National Tuberculosis Control 
Programme Practical Guidelines, 2004]. 
 
1.3.3 cART with Concomitant Antitubercular Treatment in TB/HIV Co-infected 
Children 
As TB is a common OI in HIV-infected children in developing countries, co-treatment 
with antiretroviral and antitubercular therapy is frequently indicated. The current South 
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rifampicin-based antitubercular treatment recommend standard doses of efavirenz plus 2 
NRTIs for children over 3 years old or over 10 kg, and additional ritonavir with LPV/r 
(lopinavir: ritonavir ratio 1:1) plus 2 NRTIs for children under 3 years or under 10 kg 
[National Antiretroviral Treatment Guidelines, 2004]. 
 
1.3.4 Pharmacokinetics of Efavirenz and Lopinavir in Children  
(Summarized in Appendix Table A.1 and A.2) 
1.3.4.1 Pharmacokinetics of Efavirenz in Children 
Efavirenz is highly protein bound (99%), mainly to albumin. Efavirenz is metabolized by 
cytochrome P450 (CYP) isoenzyme 2B6 and to a lesser extent CYP3A4 [Adkins et al. 
1998; Smith et al. 2001; Ward et al. 2003]. The genetic polymorphisms on CYP2B6 have 
been investigated in several studies. Allele *6 presents at high frequency (up to 30%) in 
African-American population [Klein et al. 2005; Haas et al. 2004; Wang et al. 2006]. The 
effect of CYP2B6-516-G>T polymorphism is associated with high efavirenz plasma 
concentrations, high efavirenz drug exposure and reduced oral clearance rates [Haas et al. 
2004; Tsuchiya et al. 2004; Saitoh et al. 2007; Puthanakit et al. 2009; ter Heine et al. 
2008; Cohen et al. 2009]. The recommended therapeutic range for efavirenz trough 
concentrations (Cmin) at 24 hours after dose is 1 to 4 mg/L [la Porte et al. 2006; 
www.hivpharmacology.com]. 
 
Pediatric AIDS Clinical Trials Group (PACTG) 382 study [Starr et al. 1999] has 
determined the efavirenz pharmacokinetics (PK) in children (n=50; median age 8.0 years, 
range 3.8 to 16.8) taking efavirenz capsules with the average dose of 11.7 mg/kg daily. 
The mean 24-hour area under the curve (AUC), AUC0-24, was 218 µmol·h/L (68.8 mg·h/L) 
at week 2. Close to half of the children (44%) had their efavirenz doses increased based 
on PK assessment of the AUC0-24 at 2 weeks after starting the study regimen whereas 
22% had efavirenz Cmin concentrations < 1 mg/L (personal communication, Professor 
Coutney V. Fletcher, University of Colorado Health Sciences Centre, Denver, CO, 2006). 
The mean doses of efavirenz increased to 369 mg/day (14.2 mg/kg daily) at week 6, 
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The efavirenz 24-hour concentration profiles were evaluated in 11 HIV-infected children 
at the age of 4 to 10 years receiving efavirenz doses of 10-15 mg/kg body weight daily. 
The mean efavirenz plasma Cmin was 1.29 mg/L (95% confidence interval, CI 0.89, 1.70); 
mean maximum concentration (Cmax) was 5.55 mg/L (95% CI 3.95, 7.15) and mean AUC 
was 63.6 mg·h/L (95% CI 44.2, 83.0). Seven of these 11 (63.6%) children had efavirenz 
concentrations below target range (1- 4 mg/L) [von Hentig et al. 2006]. 
 
In the International Maternal Paediatric Adolescent AIDS Clinical Trial P1058 study, 
children were receiving efavirenz doses of 350 mg/m2 (median 10.7 mg/kg, range 3.4, 
13.7) in combination with lopinavir/ritonavir had median efavirenz Cmax of 3.57 mg/L 
(range 1.4, 7.6); Tmax 3.0 hours (range 2.0, 11.9); half-life 9.94 hours (range 4.9, 27.8); 
estimated Cmin 0.77 mg/L (range 0.2, 2.5) and estimated AUC0-24 40.87 mg·h/L (range 
13.7, 86.2). Sub-therapeutic efavirenz estimated Cmin and AUC0-24 were observed in 53% 
and 14% of children, respectively [King et al. 2009]. 
 
A recent study by Hirt et al. (ANRS 12103) evaluated efavirenz PK in 48 West African 
children using a population PK model. The mean Cmin was 1.64 mg/L; Cmax 3.71 mg/L; 
AUC 65.2 mg·h/L; apparent elimination clearance (CL/F) 0.21 L/h/kg and volume of 
distribution 4.48 L/kg. It was found that 19% children had efavirenz Cmin below 
therapeutic concentration (1 mg/L), and 89% of them (8 of 9 children) weighed less than 
15 kg. They concluded that children weighing less than 15 kg were more likely to have 
sub-therapeutic concentrations [Hirt et al. 2009]. 
 
Wintergerst et al. reported the median efavirenz plasma concentration during the 
mid-dosing interval (MDI) to be 2.8 mg/L (range 0.13, 11.6) with 8.8% samples < 1 
mg/L in 33 HIV-infected children (median age 8.2 years; range 2.1, 16.7). The sampling 
time was between 8 and 20 hours in two thirds of these children [Wintergerst et al. 2008]. 
 
A recent study in 63 Thai children (median age 12.3 years; range 3.1, 18.7) found mean± 
standard deviation efavirenz plasma MDI concentration of 3.14± 3.31 mg/L. 
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between blood sampling and the prior dose in their study was 14.8± 0.8 hours [Puthanakit 
et al. 2009]. 
 
Differences in the sampling strategies, study populations and age may contribute to the 
discrepant findings. 
 
Liquid formulation of efavirenz had low bioavailability [Starr et al. 2002] and is not 
available in South Africa. 
 
1.3.4.2 PK of Lopinavir in Children 
Lopinavir is highly protein bound (98-99%) to both α1-acid glycoprotein (AAG) and 
albumin. Lopinavir is primarily metabolized by CYP3A4 isoenzyme and is also a 
substrate of P-glycoprotein (P-gp) [Sham et al. 2001; Vishnuvardhan et al. 2003; 
Agarwal et al. 2007]. The PK of lopinavir is characterized by food effect, poor 
bioavailability due to efflux by P-gp, short half-life due to rapid first-pass metabolism by 
CYP3A4 and high inter-individual variability, which precludes its use as a single PI. 
Ritonavir is a substrate and inhibitor of CYP3A4 and P-gp, which presents a favourable 
drug-drug interaction with lopinavir. Because lopinavir plasma concentrations are 
important for ARV treatment outcomes [Masquelier et al. 2002], ritonavir was 
co-administered with lopinavir at a low dose to increase lopinavir plasma concentrations 
[Sham et al. 1998]. Multiple dose studies showed that co-administration of lopinavir with 
ritonavir in a ratio of 4:1 (LPV/r) is the optimal combination to overcome the PK 
shortcomings of lopinavir as the single agent [Lal et al. 1998; Bertz et al. 1999]. The 
recommended minimum therapeutic concentration for lopinavir Cmin at 12 hours after 
dose is 1 mg/L [la Porte et al. 2006; www.hivpharmacology.com]. 
 
The PK of lopinavir was evaluated in children aged 6 months to 12 years (n= 12) 
receiving LPV/r at 230/57.5 mg/m2 twice daily. The mean± standard deviation AUC0-12 
was 72.6± 31.1 mg·h/L; Cmax 8.16± 2.94 mg/L; Tmax 3.8± 1.6 hours; Cmin 3.35± 2.14 
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Verweel et al. reported comparable lopinavir plasma concentrations in 23 children with a 
median age of 5.6 years (range 0.4, 13.2). The mean± standard deviation AUC0-12 was 
75.3± 33.7 mg·h/L; Cmax 9.33± 3.27 mg/L; Tmax 2.61± 2.09 hours; Cmin 3.68± 2.48 mg/L 
and half-life 6.59± 4.19 hours [Verweel et al. 2007]. However, suboptimal lopinavir Cmin 
concentrations (< 1 mg/L) were found in 30.4% of children. These children had 
significantly higher clearance than children with adequate Cmin. It was also found that 
children younger than 2 years were more likely to have inadequate lopinavir Cmin. An 
escalated dose of LPV/r (300/75 mg/m2) was recommended for children less than 2 years 
of age. 
 
PACTG P1030 Study in 18 infants less than 6 months of age treated with LPV/r at 
300/75 mg/m2 twice daily reported that the apparent clearance was slightly higher than 
that in the older children [Sáez-Llorens et al. 2003]. Lopinavir PK parameters were: 
median plasma pre-dose concentration 2.37 mg/L (range <0.1, 8.44); AUC 67.52 mg·h/L 
(range 23.66, 164.04); apparent clearance 0.187 L/h/kg (range 0.073, 0.610); volume of 
distribution 0.92 L/kg (range 0.34, 3.97) and half-life 3.68 hours (range 1.2, 13.11). The 
mean lopinavir Cmin and Cmax were 2.0 mg/L and 9.4 mg/L, respectively. The pre-dose 
concentrations stabilized at a higher level after the first sampling at 2 weeks, indicating 
the tolerance to the oral solution may play a role as it putatively has a horrid taste. Infants 
with viral suppression had higher lopinavir exposure than those who did not achieve 
suppression, but the difference was not statistically significant [Chadwick et al. 2008]. 
 
In the International Maternal Paediatric Adolescent AIDS Clinical Trial P1030 study, 
lopinavir plasma PK was evaluated in 9 infants less than 6 weeks of age treated with 
LPV/r at 300/75 mg/m2. Due to growth, the median actual dose of lopinavir received on 
the day of PK sampling was 267 mg/m2 (range 246, 305) twice daily. Lopinavir PK 
parameters were: median pre-dose concentration 2.22 mg/L (range 0.99, 4.87); AUC 36.6 
mg·h/L (range 27.9, 62.6); apparent clearance 0.37 L/h/kg (range 0.15, 0.75); volume of 
distribution 1.86 L/kg (range 0.80, 3.79) and half-life 3.51 hours (range 2.06, 5.80). The 
mean lopinavir Cmin and Cmax were 1.4 mg/L and 5.2 mg/L, respectively [Chadwick et al. 
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result, lopinavir exposure was lower in young infants than that in infants > 6 weeks 
[Chadwick et al. 2008] (median AUC 36.6 vs. 67.52 mg·h/L and mean Cmin 2.0 vs. 1.4 
mg/L). 
 
1.3.5 PK Drug-Drug Interactions between ARV Drugs and Antitubercular Drugs 
1.3.5.1 Plasma Drug-Drug Interactions of Efavirenz with Rifampicin 
Rifampicin is one of the most potent inducers of hepatic CYP3A4, CYP2B6 and P-gp in 
humans [Miguet et al. 1977; Rae et al. 2001; Loboz et al. 2006; Fromm et al. 2000; 
Greiner et al. 1999], thereby rifampicin has significant PK drug-drug interactions with 
NNRTIs and PIs which are substrates of these enzymes and P-gp. 
 
In a study amongst healthy adult volunteers, concomitant rifampicin reduced the 
efavirenz AUC and Cmin by 26% and 20%, respectively [Benedek et al. 1998]. Similar 
findings were reported in TB/HIV co-infected adults: the mean Cmax, Cmin and AUC 
decreased by 24%, 25% and 22%, respectively, in the presence of rifampicin. However, 
the differences did not reach statistical significance due to large inter-individual 
variability [Lopez-Cortes et al. 2002]. When the efavirenz dose was increased from 600 
mg to 800 mg daily in patients receiving concomitant rifampicin-based antitubercular 
treatment, efavirenz concentrations with concomitant rifampicin were similar to those 
observed after antitubercular treatment and decreasing the efavirenz dose to 600 mg daily 
[Lopez-Cortes et al. 2006]. Another study found a 35% reduction (95% CI -56.2%, -2.1%) 
in efavirenz TDM sample concentrations amongst 339 patients (17% on rifampicin) after 
adjustment for weight, ethnicity and concomitant zidovudine [Stöhr et al. 2008]. 
However, a study in Thai patients showed that the median efavirenz MDI concentrations 
were comparable amongst patients receiving efavirenz at 600 mg or at 800 mg daily with 
concomitant rifampicin. Racial differences and the lower body mass index (BMI) of Thai 
patients could explain the different findings [Manosuthi et al. 2005]. The virological and 
immunological outcomes were similar at 48 weeks in both groups [Manosuthi et al. 
2006]. An efficacy study in South African HIV-infected adults also reported the 
comparable virological outcomes in patients receiving standard 600 mg daily dose of 
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Two studies in South African HIV-infected adults on standard dose of efavirenz showed 
that there was no significant reduction in efavirenz concentrations during compared to 
after rifampicin-based antitubercular therapy [Friedland et al. 2006; Cohen et al. 2009]. 
 
Although, some authorities recommend increasing the efavirenz dose by 25% when given 
with concomitant rifampicin to compensate the reduction in efavirenz concentrations 
[Panel on Antiretroviral Guidelines for Adult and Adolescents, 2008], there is currently not 
consensus on optimal dosing of efavirenz with rifampicin. No studies have evaluated 
efavirenz concentrations in children receiving concomitant rifampicin. 
 
1.3.5.2 Plasma Drug-Drug Interactions of Lopinavir with Rifampicin 
The interaction between rifampicin and lopinavir (in combination with ritonavir, LPV/r, 
400/100 mg twice daily) was evaluated in a study amongst healthy adult volunteers. 
Rifampicin reduced lopinavir plasma AUC and Cmin by 75 and 99%, respectively [Bertz 
et al. 2000]. For this reason, co-administration of rifampicin and LPV/r is not 
recommended. A further study in healthy adult volunteers [la Porte et al. 2004] showed 
that adding ritonavir to LPV/r (lopinavir: ritonavir ratio of 1:1) with concomitant 
rifampicin resulted in acceptable peak and trough lopinavir concentrations, suggesting 
this adjusted dose regimens of LPV/r could be used with rifampicin-based antitubercular 
treatment in TB/HIV co-infected patients. However, this approach has not been evaluated 
in TB/HIV co-infected children receiving concomitant rifampicin-based antitubercular 
treatment. 
 
1.3.5.3 Drug-Drug Interactions between ARV Drugs with Isoniazid 
Isoniazid, which is given in combination with rifampicin in antitubercular treatment, has 
been shown in in vitro studies to inhibit CYP3A4 and CYP 2A6 amongst other enzymes 
[Wen et al. 2002]. 
 
When CYP2B6 function is impaired, accessory metabolic pathways may control the rate 
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accessory pathways are CYP3A and CYP2A6. Thus, there is potential for drug-drug 
interactions between isoniazid and the ARV drugs, including efavirenz and lopinavir. 
 
1.3.5.4 Drug-Drug Interactions between ARV Drugs and Rifampicin at Cellular 
Level 
P-gp belongs to a family of plasma membrane proteins encoded by the multidrug 
resistance (MDR) genes and functions as an energy-dependent efflux pump which 
removes drugs from the cell membrane and cytoplasm. Many substrates metabolized by 
CYP3A4 are also substrates of P-gp, including ARV drugs. Furthermore, P-gp is 
expressed in the blood-brain barrier, liver, kidney, as well as peripheral blood 
mononuclear cells (PBMCs) [Coon et al. 1991]. Multidrug resistance-associated protein 
(MRP) is another energy-dependent transmembrane efflux pump, which is also expressed 
on PBMCs [Abbaszadegan et al. 1994; Oselin et al. 2003]. Rifampicin is the inducer of 
P-gp. Efavirenz is a substrate for P-gp [Chandler et al. 2003], and PIs are not only a 
substrate for P-gp [Profit et al. 1999; Washington et al. 1998; Lee et al. 1998; Gutmann 
et al. 1999] but also for MRP [Gutmann et al. 1999; Srinivas et al. 1998; Agarwal et al. 
2007]. Concomitant rifampicin may also affect the concentrations of these ARV drugs at 
the cellular level through actions on these transmembrane drug transporters. 
 
1.4 The Importance of Measurement of Efavirenz and Lopinavir Plasma 
Concentrations in HIV-infected Children with or without TB 
There is great importance to evaluate efavirenz and lopinavir plasma concentrations in 
children, particularly in African children, because: 
 
1.4.1 Children Are Different from Adults 
There is limited information on PK of ARV drugs in children. In the absence of complete 
PK data or established dosing guidelines, the doses of ARV drugs in children were 
extrapolated based on the established dose for adults. The PK of these drugs may differ 
greatly between children and adults because of age-associated changes in body 
composition and organ function are dynamic and can be discordant during the first 










Chapter 1 Introduction 
 12 
intestinal motility can affect on the absorption of drugs. Relatively large extracellular and 
total-body water spaces, changes in the composition and amount of circulating plasma 
proteins, such as albumin and AAG, influence the distribution of highly bound drugs. 
Difference in expression of drug transporting protein such as P-gp also can alter the drug 
distribution. Maturation of drug-metabolizing enzyme activity may account for 
differences in drug metabolism and clearance. In particular, hepatic enzyme activity 
changes with age. It increases to adult levels during infancy, and then exceeds adult 
levels at 1 to 4 years of age, and then returns back to adult levels after puberty. 
Age-associated factors can also affect renal function and therefore drug elimination 
[Kearns et al. 2003; King et al. 2002]. 
 
1.4.2 Disease States and Concomitant Treatment May Alter the PK of ARV drugs 
It is important to measure drug concentrations in diseased patients rather than in healthy 
volunteers. TB/HIV co-infection may induce biochemical changes, including elevated 
AAG level, altered P-gp expression and drug metabolizing enzyme activity in patients 
[Kremer et al. 1988; Andreana et al. 1996]. Disease states may also cause physiological 
changes, for example wasting, which have important impact on drug distribution. 
 
The major concerns of concomitant antitubercular treatment are the PK drug-drug 
interactions between rifampicin and efavirenz and lopinavir, respectively. However, there 
are no studies evaluating the effect of rifampicin-based antitubercular treatment on the 
ARV drug plasma concentrations in children. 
 
1.4.3 Drug Concentrations Affect treatment Tolerance and Response 
Studies have shown associations between treatment efficacy and toxicity with plasma 
concentrations of efavirenz and lopinavir [Marzolini et al. 2001; Csajka et al. 2003; Joshi 
et al. 1999; van Leth et al. 2006; Ståhle et al. 2004; González de Requena et al. 2004; 
Masquelier et al. 2002; van Rossum et al. 2002]. Maintaining efavirenz and lopinavir 
plasma concentrations above the minimum therapeutic ranges throughout the dosing 
interval is crucial for delaying the development of drug-resistant mutants and ensuring 
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inter-individual variability. It is important to evaluate plasma concentrations of these 
drugs in children dosed according to current treatment guidelines. 
 
1.4.4 Lack of Paediatric PK Information from High Burden Countries 
African children are a population vulnerable to HIV-infection. Although majority of the 
HIV-infected children are living in Africa, there is no data regarding efavirenz and 
lopinavir PK in African paediatric populations. Children in Africa are subject to different 
genomics and dietary structure than children in America or Europe, which can alter the 
PK measurements of ARV drugs [Klein et al. 2005; Haas et al. 2004; Wang et al. 2006; 
Saitoh et al. 2007; Bhardwaj et al. 2002; Yeh et al. 1998]. 
 
1.5 The Urgency of New Method Development and Validation for ARV drug 
Concentration Assay 
Serum and plasma are the common matrices for ARV drug concentration testing. 
Conventional methods require extensive sample collection and expensive processing 
techniques, storage and transportation conditions which are difficult or unavailable in 
resource-limited settings. Furthermore, paediatric PK studies are often limited by the 
volume of blood required. There is an urgent need to develop and validate a field friendly 
method which requires small volumes of blood, and inexpensive processing and storage 
conditions. A liquid chromatography/tandem mass spectrometry (LC/MS/MS) method 
was developed for ARV concentration measurement in dried blood spot (DBS) samples 
by Koal et al. This study showed a linear correlation between DBS and plasma 
concentrations in 70 samples with total of 6 ARV drugs [Koal et al. 2005]. However, the 
use of DBS method has not been validated in a paediatric study or amongst patients. 
 
1.6 Intracellular ARV Drug Concentrations in HIV-infected Patients (in vivo) 
Therapeutic drug monitoring (TDM) is recommended to optimize efficacy and to reduce 
toxicity of ARV treatment by maintaining drug plasma concentrations within their 
therapeutic ranges. However, the site of action of ARV drugs is inside the HIV-infected 
cells. Therefore, the measurement of intracellular drug concentrations can provide a 










Chapter 1 Introduction 
 14 
 
To date, several studies have investigated the intracellular concentrations of efavirenz, 
lopinavir and ritonavir in HIV-infected adults. The previously reported intracellular/ 
plasma concentration ratios for efavirenz were: median 0.9 [Rotger et al. 2005]; 
geometric mean 0.69 (geometric coefficient of variation 101) [Colombo et al. 2006]; and 
median 1.3 (range 0.7- 3.3) [Almond et al. 2005 a]. 
 
When lopinavir and ritonavir were given in a combination (LPV/r; 400/100 mg twice 
daily), the reported intracellular/plasma concentration ratios of lopinavir from previous 
studies were: median 1.18 (interquartile range, IQR 0.74, 2.06) [Crommentuyn et al. 
2004]; median 1.55 (range 0.67, 3.80) [Hoggard et al. 2002]; and mean 0.65 (standard 
error 0.12) [Colombo et al. 2004]. Whereas, the intracellular/plasma concentration ratios 
of ritonavir in the combination with lopinavir were median 4.59 (IQR 3.20, 7.70) 
[Crommentuyn et al. 2004]; median 5.28 [Hoggard et al. 2002]; and mean 0.94 (standard 
error 0.18) [Colombo et al. 2004]. The median intracellular/plasma concentration ratios 
of ritonavir when taken alone at a dose of 500- 600 mg twice daily was 1.00 (range 0.60, 
2.28) [Khoo et al. 2002]. Breilh et al. reported much higher intracellular/plasma 
concentration ratios of lopinavir Cmin in the virological success group than those in the 
failure group: median 3.2 (IQR 2.6, 3.8) vs. 2.3 (IQR 1.9, 2.8) and median 2.4 (IQR 1.6, 
3.1) vs. 1.4 (IQR 1.3, 1.7) at 1 month and 6 months after LPV/r administration (400/100 
mg or 533/133 mg, twice daily), respectively. The intracellular lopinavir Cmin efficacy 
threshold was defined at 8 mg/L [Breilh et al. 2004]. (Summarized in Appendix Table 
A.3) 
 
To our knowledge, there is no data available on intracellular accumulation 
(intracellular/plasma concentration ratios) of these ARV drugs in HIV-infected children 
with or without TB and antitubercular treatment. As mentioned earlier, age-related factors 
may induce the biological and physiological changes and therefore influence intracellular 
accumulation. Co-infection with TB and rifampicin-based antitubercular treatment may 
alter the protein binding of efavirenz and lopinavir. For these highly protein bound ARV 
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of free drug available for entering the cells. Furthermore, efavirenz, lopinavir and 
ritonavir are substrates of several drug efflux transporters. The induction effect of 
concomitant rifampicin on these drug efflux transporters may also interfere with the 
intracellular concentrations of these 3 ARV drugs. 
 
1.7 In vitro Intracellular ARV Drug Accumulation  
Intracellular accumulation of ARV drugs is a result of influx and efflux processes. A 
study by Janneh et al. demonstrated the effects of several efflux transport protein 
inhibitors on the intracellular accumulation of saquinavir in human PBMCs [Janneh et al. 
2005]. However, the study may have used much higher drug concentrations than those 
found in patients. Moreover, ritonavir and rifampicin are known inhibitor and inducer of 
energy-dependent drug efflux proteins, respectively, and they are frequently 
co-administered with efavirenz and lopinavir. Therefore, investigations on the in vitro 
interactions between low-dose ritonavir (as pharmacoenhancer, in combination with 
lopinavir) and rifampicin with efavirenz and lopinavir in human PBMCs at the 
concentrations representing average drug concentrations in patients could give some 
insights into the effects of drug-drug interactions at the cellular level. 
 
1.8 The Objectives of This Study 
1. To define efavirenz and lopinavir/ritonavir plasma concentrations in African children 
receiving cART with and without concomitant rifampicin-based antitubercular 
treatment 
 To develop and validate a simple and rapid ARV drug concentration testing 
method requiring small volumes of plasma using LC/MS/MS 
 To evaluate the effect of concomitant rifampicin-based antitubercular treatment 
on efavirenz concentrations as well as the concentrations of lopinavir/ritonavir in 
the adjusted dose regimens (lopinavir: ritonavir ratio of 1:1) 
 
2. To develop and validate the use of the DBS method to facilitate the measurement of 
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 To develop and validate LC/MS/MS method for ARV concentration assay in 
DBS sample 
 To define the correlation between DBS and plasma concentrations for efavirenz, 
lopinavir and ritonavir 
 To identify factors that affecting the correlation between DBS and plasma 
concentrations 
 To test the stability of efavirenz, lopinavir and ritonavir in DBS sample 
 
3. To determine intracellular efavirenz, lopinavir and ritonavir trough concentrations in 
HIV-infected children with and without concomitant rifampicin-based antitubercular 
treatment (in vivo) 
 To develop and validate LC/MS/MS method for intracellular ARV concentration 
assay 
 
4. To evaluate the effects of rifampicin and ritonavir on efavirenz and lopinavir 


























Materials and Methods 
 
 
2.1 Plasma Sample Preparation and Concentration Assay 
2.1.1 Preparation of Plasma Sample 
Whole blood samples (1.2 mL of each sample) from the efavirenz and lopinavir-ritonavir 
study were collect in lithium-heparin tubes at each time point of PK visit. An aliquot of 
50 µL whole blood was removed from each sample to make dried blood spot, which is 
described in Section 2.2.1. The rest blood was centrifuged (within 30 minutes after blood 
taken) at 700 ×g for 5 minutes and the plasma was stored immediately at -80 ºC while 
awaiting quantification of concentrations. 
 
Efavirenz, lopinavir and ritonavir plasma concentrations were determined simultaneously 
by LC/MS/MS (API 4000 triple quadrupole MS/MS Applied Biosystems, South Africa) 
using a modification of the method by Chi et al. [Chi et al. 2002], in the laboratory of the 
Division of Clinical Pharmacology, University of Cape Town. An aliquot of 500 µL of 
precipitation reagent (80% methanol: 20% 0.2M ZnSO4 v/v) (methanol from Merck 
KGaA, Darmstadt, Germany; ZnSO4 from Sigma Chemical Co.) with reserpine (Sigma 
Chemical Co.) at 0.4 µg/mL as internal standard was added to 50 µL aliquot of plasma 
and vortexed at high speed for 15 seconds. The suspension was then sonicated for 10 
minutes and centrifuged at 12000 ×g for 5 minutes to pellet the precipitated proteins and 
give a clear supernatant. These clear extracts were transferred to vial inserts and placed in 
the autosampler tray for injection onto LC/MS/MS column (Phenomenex Gemini C18, 
50× 2.00 mm, with 5 micron particle size packing). 
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Mobile phase A was 10% methanol and mobile phase B was 90% methanol: 10% 10mM 
of ammonium acetate in 0.1% acetic acid v/v. The flow gradient was initially 100% of A 
for 0.20 minute, switched to 100% B from 0.21 minutes, held at 100% B for 2.79 minutes. 
Then returned to 100% A over 0.10 minute, held for a further 3.90 minutes prior to the 
injection of another sample. The total run time for each sample was 7.00 minutes. The 
flow rate of mobile phase was kept constantly at 500 µL/minute. The volume of injection 
was 5 µL. 
 
The plasma calibration curves of efavirenz (Merck Research Laboratories, Rahway N.J., 
USA) lopinavir and ritonavir (both from Abbott Laboratories, North Chicago, IL 60064, 
USA) were linear over the range of 0.20-15.00 mg/L, 0.05-20 mg/L and 0.025- 5 mg/L, 
respectively (Figure 2.1). Plasma calibration curves were prepared by spiking efavirenz, 
lopinavir and ritonavir in drug-free plasma at each calibration concentration. Three 
quality controls were prepared in the same manner (0.3 mg/L, 4 mg/L and 11 mg/L for 
efavirenz; 0.15mg/L, 8 mg/L and 16 mg/L for lopinavir; 0.075 mg/L, 1.5 mg/L and 3.5 
mg/L for ritonavir). The lower limit of quantification (LLOQ) was 0.20 mg/L, 0.05 mg/L 
and 0.025 mg/L for efavirenz, lopinavir and ritonavir, respectively (Figure 2.2). Any 
sample with plasma concentration below the LLOQ was treated as 40% of LLOQ 
concentration in the data analysis. Any sample with plasma concentration higher than the 
upper limits of quantification was diluted with drug-free plasma and reanalyzed. 
 
For efavirenz plasma assay: Accuracy ranged from 90.55% to 109.55%. The intra-day 
and inter-day precisions ranged from 1.34% to 9.61% and from 2.23% to 7.04%, 
respectively. For lopinavir assay: Accuracy ranged from 90.57% to 109.78%. The 
intra-day and inter-day precisions ranged from 0.36% to 5.47% and from 0.73% to 5.43%, 
respectively. For ritonavir assay: Accuracy ranged from 93.26% to 108.50%. The 
intra-day and inter-day precisions ranged from 1.10% to 8.33% and from 0.94% to 5.75%, 
respectively. The laboratory participates in the International Interlaboratory Control 
Programme of Stichting Kwaliteitsbewaking Klinische Geneesmiddelanalyse en 
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Figure 2.1 Plasma calibration curves 
a) Efavirenz plasma calibration curve 
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c) Ritonavir plasma calibration curve 
 
 
Figure 2.2 Chromatograms of plasma LLOQ 
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c) Chromatogram of ritonavir LLOQ 
 
 
2.2 DBS Sample Preparation and Concentration Assay 
2.2.1 Preparation of DBS Sample 
DBS samples were obtained from efavirenz and lopinavir-ritonavir studies during plasma 
sampling. Exactly 50 µL from heparinized whole blood sample was spotted within 30 
minutes after blood sampling onto 903 TFN filter paper card with pre-marked circles 
(Munktell, Niederschlag, Germany). The cards were dried at room temperature for 2 
hours and stored in sealed plastic bags with desiccant at 4 ºC. 
 
Each blood spot was cut into fine pieces and soaked in 100 µL of HPLC grade water 
(Merck KGaA, Darmstadt, Germany) for 10 minutes. An aliquot of 200 µL of 
precipitation reagent (50% methanol: 50% 0.2M ZnSO4 v/v) with reserpine at 0.6 µg/mL 
as internal standard was added to the sample and vortexed at high speed for 20 second. 
The mixture was then sonicated for further 20 minutes and centrifuged at 12000 ×g for 
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autosampler tray for injection onto LC/MS/MS column [Koal et al. 2005]. 
 
2.2.2 DBS ARV Concentration Assay by LC/MS/MS 
DBS concentrations of efavirenz, lopinavir and ritonavir were quantified simultaneously 
by the same validated LC/MS/MS method used in plasma ARV drug concentration assay 
(Section 2.1.2). The DBS calibration curves were prepared by spiking ARV drugs in 
drug-free fresh whole blood at each calibration concentration, from which 50 µL of blood 
was spotted on filter paper. Three quality controls were prepared in the same manner (0.3 
mg/L, 4 mg/L and 11 mg/L for efavirenz; 0.15mg/L, 8 mg/L and 16 mg/L for lopinavir; 
0.075 mg/L, 1.5 mg/L and 3.5 mg/L for ritonavir). The calibration curve was linear over 
the range of 0.2- 15 mg/L, 0.05- 20 mg/L, and 0.025- 5 mg/L for efavirenz, lopinavir and 
ritonavir, respectively (Figure 2.3). Any sample with concentration below LLOQ was 
treated as 40% of the LLOQ concentration in the data analysis. Any sample with the 
concentration above the upper limits of quantification was diluted with DBS precipitation 
reagent and reanalyzed. The laboratory participates in the International Interlaboratory 
Control Programme of Stichting Kwaliteitsbewaking Klinische Geneesmiddelanalyse en 
Toxicologie (KKGT; Hague, the Netherlands) on an ongoing basis. 
 
For efavirenz DBS assay: Accuracy ranged from 91.92% to 109.56%. The intra-day and 
inter-day precisions ranged from 0.34% to 7.57% and from 4.42% to 8.37%, respectively. 
For lopinavir assay: Accuracy ranged from 90.00% to 112.19%. The intra-day and 
inter-day precisions ranged from 0.65% to 7.24% and from 2.15% to 5.87%, respectively. 
For ritonavir assay: Accuracy ranged from 91.53% to 112.19%. The intra-day and 
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Figure 2.3 DBS calibration curves 
a) Efavirenz DBS calibration curve 
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c) Ritonavir DBS calibration curve 
 
 
Figure 2.4 Chromatograms of DBS LLOQ 
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c) Chromatogram of ritonavir LLOQ 
 
 
2.2.3 Stabilities of ARV Drugs in DBS Samples 
The stabilities of efavirenz, lopinavir and ritonavir in DBS samples were tested at 37 ºC 
for 7 days. The stabilities of two drying methods were also tested: 1) drying under direct 
sunlight for 2 hours and 2) using hair drier at higher setting for 3 minutes. 
 
2.3 In vitro ARV Drug Accumulation Assay 
2.3.1 Isolation of Human PBMCs from Leukoreduction Chambers 
The leukoreduction chambers were donated by Western Province Blood Transfusion 
Service Centre in Cape Town at the conclusion of the aphaeresis procedures. Tubing of 
leukoreduction chambers was sealed before removing the chamber from the aphaeresis 
instrument (Trima Accel®, Gambro BCT, Inc. Lakewood, CO USA). Human PBMCs 
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The leukoreduction chamber was rinsed with a 60 mL syringe fitted with 22-gauge needle 
by 50 mL of phosphate buffered saline (PBS) solution containing 2% of foetal calf serum 
(FCS, Highveld Biological PTY LTD, Lyndhurst, RSA). The leukocyte suspension was 
equally divided to 2 portions (approximately 30 mL of each portion). In two 50 
mL-Falcon® tubes containing 15 mL of Histopaque solution (Sigma Chemical Co.), 30 
mL of leukocyte suspension was carefully loaded without disturbing the interface of the 
two solution. The biphasic solution was centrifuged at 350 ×g for 30 minutes at room 
temperature, with slow acceleration and no break. The layer at interface was collected 
from the two tubes and pooled into one 50 mL tube. The interface layer was washed with 
50 mL of PBS and centrifuged at 650 ×g for 10 minutes at room temperature, with break 
at low setting. The supernatant was aspirated off, and cell pellet was re-suspended in 50 
mL of PBS, inverted gently for 10 times. The wash step was repeated twice [Colombo et 
al. 2005]. After the final wash step, the cell pellet was re-suspended in 25-30 mL of PBS 
solution, from which two 10 µL- aliquots of suspension were removed. One aliquot was 
diluted and mounted onto a Bright Microscope Line Counting Chamber (Hausser 
Scientific Company) under a coverslip for cell counting. Another aliquot was stained with 
same volume (10 µL) of Trypan blue solution for cell viability calculation. The formula 
for cell viability calculation is as follows: 
 
Number of viable (unstained) PBMC 
% of viability= ———————————————— × 100 
                  Total number of PBMC 
 
Depend on the cell count and viability, the suspension was centrifuged and re-suspended 
in RPMI-1640 growth media (Dutch Modification with NaHCO3 at 1 g/L and 20 mM 
HEPES without L-glutamine; from Sigma Chemical Co.) to make a cell stock solution 
with a concentration of 8×106 cells/mL. 
 
2.3.2 In vitro ARV Drug Intracellular Accumulation Experiment 
Efavirenz and lopinavir were spiked in 500 µL of RPMI growth media containing 10% of 
FCS in the absence and presence of drug efflux protein inhibitors (verapamil at 50 µM, 
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(rifampicin at 4 mg/L). The same volume of cell stock solution was added (the final cell 
count= 4×106 cells/mL) and incubated at 37 ºC for half an hour. The final concentration 
for efavirenz and lopinavir was 1.5 and 5 mg/L, respectively. The PBMC samples were 
then centrifuged at 350 ×g at 4 ºC for 5 minutes. The supernatant was aspirated off. The 
bottom of the tube which contained cell pellet was clipped off into another 1.5 mL 
polypropylene Eppendorf tube and kept at -20 ºC for concentration testing. 
 
2.3.3 Intracellular ARV Concentration Testing 
2.3.3.1 Preparation of Blank Control PBMCs 
The blank control PBMCs were used for the preparation of LC/MS/MS calibration and 
quality control samples. PBMCs were isolated from leukoreduction chamber as described 
in Section 2.3.1. After cell counting and viability calculation, appropriate volume of PBS 
was added to the cell suspension to provide a concentration of 4×106 cells/mL. The 
diluted suspension was distributed as 1 mL-aliquots in 1.5 mL polypropylene Eppendorf 
tubes. These 1 mL-aliquots were centrifuged at 350 ×g for 5 minutes. The supernatant 
was aspirated off, leaving cell pellets at the bottom of the tubes. The blank PBMCs were 
stored at -20 ºC. 
 
2.3.3.2 Calibration Curve and Quality Control 
Working solution contains the mixture of 50% methanol and 50% of HPLC-grade water 
with 0.05 µg/mL of reserpine as internal standard. The stock solution containing 
efavirenz, lopinavir and ritonavir at 1 mg/mL in methanol was diluted with working 
solution to obtain 9 concentrations for the calibration curve (0.1, 0.25, 0.5, 1.0, 5.0, 10.0, 
50.0, 75.0, 100.0 ng/mL) and 3 concentrations for quality control (0.75, 20.0, 80.0 
ng/mL). 
 
2.3.3.3 Extraction of ARV from PBMCs and LC/MS/MS Assay 
A 300 µL-aliquot of calibration and quality control with reported concentrations (Section 
2.3.3.2) was added to blank PBMC pellet. An aliquot of 500 µL of working solution was 
added to each polypropylene Eppendorf tube containing sample from in vitro ARV drug 
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speed for 30 seconds and subsequently sonicated for 20 minutes. Samples were shaked 
for 3 hours by a vortex machine (at level 4) used as a shaker. Samples were then 
centrifuged at 12000 ×g for 5 minutes at room temperature. The clear extracts were 
transferred to vial inserts and placed in the autosampler tray for injection onto 
LC/MS/MS column. 
 
Intracellular concentrations of efavirenz, lopinavir and ritonavir were quantified 
simultaneously by the same validated LC/MS/MS method used in plasma and DBS ARV 
drug concentration assays (Section 2.1.2). The efavirenz, lopinavir and ritonavir 
calibration curves for intracellular concentration testing were linear over the range of 
0.1-100.0 ng/mL (Figure 2.5). The LLOQ was 0.1 ng/mL for these 3 drugs (Figure 2.6). 
Any sample with plasma concentration below the LLOQ was treated as 40% of LLOQ 
concentration in the data analysis. Any sample with the concentration above the upper 
limits of quantification was diluted with working solution and reanalyzed. 
 
For efavirenz plasma assay: Accuracy ranged from 87.93% to 115.76%. The intra-day 
and inter-day precisions ranged from 2.56% to 14.62% and from 1.12% to 9.39%, 
respectively. For lopinavir assay: Accuracy ranged from 93.51% to 108.42%. The 
intra-day and inter-day precisions ranged from 0.01% to 24.32% and from 1.13% to 
32.02%, respectively. For ritonavir assay: Accuracy ranged from 87.87% to 110.43%. 
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Figure 2.5 Intracellular calibration curves 
a) Efavirenz intracellular calibration curve 
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c) Ritonavir intracellular calibration curve 
 
 
Figure 2.6 Chromatograms of intracellular LLOQ 
a) Efavirenz intracellular LLOQ 
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c) Ritonavir intracellular LLOQ 
 
 
2.3.4 Quantification of Drug Concentration in PBMCs 
The relative drug concentrations were calculated form calibration curve. However, the 
number of cells needed to be taken into account. The concentrations must be converted to 
express the amount of drug in cell volume, assuming a cell volume of 0.4 pL for each 
PBMC [Furman et al. 1986]. The formula used for calculation of intracellular 
concentration was: 
 
Total amount of drug 
Intracellular concentration (mg/L)=  ———————————————————— 
PBMC volume× Total viable cell number/mL 
 
The total amount of drug was obtained by multiplying the relative drug concentration by 
0.5 mL (the volume of working solution added to extract each sample). The viable cell 
number/mL in each pellet in this experiment was 4×106 cells/mL. Data were expressed as 
cellular accumulation ratios (the ratio of efavirenz and lopinavir concentrations 
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2.4 In vivo Intracellular ARV Drug Concentration Testing 
2.4.1 Isolation of Patient PBMCs 
PBMCs were isolated from HIV-infected children receiving efavirenz or LPV/r, using the 
BD VacutainerTM CPTTM Tubes (Becton Dickinson, Franklin Lakes, NJ, USA), which 
contain citrate as anticoagulant, a polyester gel layer, and a Ficoll Hypaque solution 
enabling the direct separation of mononuclear cells from other blood components. 
Approximately 4 mL of whole blood from each child was collected into a 4mL CPTTM tube 
and centrifuged immediately at 1800 ×g for 30 minutes at 4 ºC, without brake. The whitish 
interface which contains mononuclear cells was transferred into a 15 mL polypropylene 
centrifuge tube. The collected cells were washed with 10 mL of cold PBS solution (4 ºC) 
and centrifuged at 300 ×g for 15 min at 4 ºC with brake at low setting. The supernatant was 
discarded. The washing procedure was repeated twice [Becton Dickinson VacutainerTM 
system]. Supernatant wash solution was completely aspirated off after the third wash and 
an exact 1 mL of PBS was added to the cell pellet and carefully homogenized. One 10 
µL-aliquot from the cell suspension was removed and diluted for cell counting. Another 
10 µL-aliquot was taken out and stained with the same volume of Trypan blue solution 
for cell viability calculation. The remaining 980 µL cell suspension was centrifuged at 
350 ×g for 5 minutes at 4 ºC. The supernatant was aspirated off, leaving the PBMC pellet 
at the bottom of the vial which was immediately stored at −20 ºC while waiting to be 
analyzed. 
 
2.4.2 In vivo Intracellular Drug Extraction and LC/MS/MS Assay 
The same procedures were followed as described in Section 2.3.3.3. The assay was 
performed in the laboratory of the Division of Clinical Pharmacology, University of Cape 
Town. 
 
2.4.3 Quantification of in vivo Intracellular Drug Concentration 
The formula used for calculation of intracellular concentration was stated in Section 2.3.4. 
The total amount of drug was obtained by multiplying the relative drug concentration by 
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number/mL was obtained by multiplying cell count with cell viability in each sample. 













































Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-infected 




The non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz, is recommended 
by the World Health Organization as a preferred first-line antiretroviral agent for children 
older than 3 years [WHO 2006]. As efavirenz is metabolized primarily by hepatic 
cytochrome P450 (CYP) 2B6, and rifampicin induces the expression of this enzyme, the 
potential pharmacokinetic interaction is a concern in HIV-infected children receiving 
concurrent treatment for TB and HIV. Adult studies show that concomitant rifampicin 
tends to reduce mean efavirenz plasma concentrations [Lopez-Cortes et al. 2002], and 
some authorities recommend increasing the efavirenz dose by 25% to compensate [Panel 
on Antiretroviral Guidelines for Adult and Adolescents, 2008]. No study has evaluated 
the effect of rifampicin-based antitubercular treatment on efavirenz plasma 
concentrations in children. 
 
As low and high efavirenz concentrations in adults have been associated with virological 
failure and central nervous system side-effects, respectively [Marzolini et al. 2001; 
Csajka et al. 2003; Joshi 1999; van Leth et al. 2006; Ståhle et al. 2004; González de 
Requena et al. 2004; Puthanakit et al. 2009; Cohen et al. 2009], it is important to 
maintain efavirenz trough concentrations within the recommended therapeutic range (1 to 
4 mg/L) [la Porte et al. 2006; www.hivpharmacology.com]. The marked inter-patient and 
low intra-patient variability suggest that individual drug concentration monitoring may be 
a useful strategy for optimizing treatment [Marzolini et al. 2001]. However, in 
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concentration-controlled dosing is not available outside of the research environment. 
There is a paucity of information about efavirenz plasma concentrations in children, 
especially African children. 
 
In this chapter, a clinic-based, cross-sectional comparative study is described, in which the 
sparse sampling method was used to evaluate efavirenz plasma concentrations and 
determine the effect of rifampicin on efavirenz pharmacokinetics in African HIV-infected 




A total of 30 children (aged 3-15 years old or weighing> 10kg) were enrolled: 15 
TB/HIV co-infected children receiving standard doses of efavirenz as part of cART and 
rifampicin-based antitubercular treatment, and 15 HIV-infected children without 
tuberculosis receiving standard doses of efavirenz based cART. All children were dosed 
according to weight and the doses of efavirenz capsules were titrated to the nearest 50 mg 
in accordance with the Stocrin® product information leaflet [Merck Sharp & Dohme 
Limited, Modderfontein, South Africa, 1999]. Rifampicin-based antitubercular treatment 
regimens were administered in accordance with the South African National Tuberculosis 
Treatment Programme. Children were recruited at three sites: the HIV Clinic at Red 
Cross Children’s Hospital, Cape Town; the Harriet Shezi Children’s Clinic, Chris Hani 
Baragwanath Hospital, Soweto; and Brooklyn Chest Hospital, Cape Town. Institutional 
approval of the study was granted by the research ethics committees of the University of 
Cape Town, Stellenbosch University and the University of the Witwatersrand. 
 
Additional group of 5 TB/HIV co-infected children was enrolled to evaluate the method 
used to estimate efavirenz 24-hour Cmin. 
 
Exclusion criteria were: renal, hepatic, or intestinal disease (including malabsorption or 
diarrhoea); other active opportunistic infections; recent exposure to drugs described to 
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in the preceding 3 days. They were accompanied by a parent or legal guardian who 
provided written informed consent to participate in the study, and children older than 7 
years gave their own assent. 
 
3.2.2 Study Design 
Co-infected children were on treatment for TB and HIV for at least 4 weeks before PK 
evaluation. Efavirenz plasma concentrations were evaluated a second time in this group 
of children at least 4 weeks after completing antitubercular treatment. The children 
without TB were established on cART for at least 4 weeks before efavirenz 
concentrations were measured. At least 12 hours after the dose of efavirenz, 3 blood 
samples were collected during a clinic visit with a time interval of no less than 2 hours 
between each sample. For the extra group of TB/HIV co-infected children, after 
collecting of 3 samples on 2 occasions described above, the additional 4th sample was 
collected at 24 hours after previous dose of efavirenz on both occasions.  The exact 
times of blood sampling were recorded and the time of efavirenz ingestion the previous 
evening was reported by the accompanying adult. 
 
Adults accompanying the participants were asked about treatment adherence to cART 
during the 3 days prior to PK sampling using a questionnaire. Viral load was tested by 
NASBA EasyQ (Biomerieux, Boxtel, the Netherlands). Viral load monitoring was 
performed at 6 month intervals as part of routine management. 
 
3.2.3 Data Analysis 
The plasma concentrations of efavirenz were determined by LC/MS/MS. The detailed 
methods were described in the Materials and Methods Chapter (Section 2.1). Estimation 
of the Cmin concentration of efavirenz in plasma at 24 hours after dose administration 
assumed first-order elimination of the drug during the sampling period [Kappelhoff et al. 
2005]. The estimated Cmin was determined by extrapolation of the log-linear regression 
line of the 3 concentration vs. time points to 24 hours after the reported time of the dose 
given in the previous evening. The elimination rate constant (k) was defined as the 
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from k (half-life= 0.693/k). The MDI concentration of efavirenz was defined as the mean 
of the plasma concentrations taken between 16 and 20 hours after dose administration. 
 
3.2.4 Statistical Analysis 
Stata version 8.2 (Stata Corp., College Station, TX) was used to compute summary 
statistics, and to perform statistical analyses. Wilcoxon ranksum test (RS) and Wilcoxon 
matched-pairs signed-ranks test (SR) were used for independent groups and paired 
observations, respectively, with non-normally distributed data. The relative prediction 
error (bias) of estimation was the difference between the estimated and the true value 
relative to the true measurement. The relative imprecision was the standard deviation of 
the relative prediction error. The sensitivity and specificity were calculated using the 
following formulae: 
 
number of true positive 
Sensitivity= ———————————————————————— 
number of true positive+ number of false negative 
 
number of true negative 
Specificity= ———————————————————————— 
number of true negative+ number of false positive 
 
3.3 Results 
3.3.1 Efavirenz Study 
The children’s general characteristics are summarized in Table 3.1. The co-administered 
NRTIs were stavudine plus lamivudine in 28 (93%) children, lamivudine plus zidovudine 
in 1 (3%), and zidovudine plus didanosine in 1 (3%) child. The median durations of 
cART in TB/HIV co-infected children prior to the first and second pharmacokinetic 
assessments were 12 weeks (range 4, 55) and 28 weeks (range 20, 78), respectively. The 
median duration of cART in control group was 71 weeks (range 8, 173). Two children 
were under 3 years: 1 with TB/HIV co-infection (1.42 and 2.08 years, during and after 
antitubercular treatment, respectively) and the other was in the control group (2.25 years); 
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Three efavirenz concentrations were determined in all participants at each 
pharmacokinetic assessment. The efavirenz concentrations ranged from 0.36 to 10.60 
mg/L and the sampling times ranged from 11.9 to 24.0 hours after dose administration. 
The regression lines used to estimate the Cmin values had a median R-squared value of 
0.95 (IQR 0.85, 0.98). Median R-squared value was slightly reduced after antitubercular 
treatment when compared with during antitubercular treatment in the same group of 
children (median 0.88 IQR 0.38, 0.98 and 0.95 IQR 0.85, 0.98, respectively; SR p= 0.094). 
The estimated efavirenz plasma Cmin in TB/HIV co-infected children during and after 
rifampicin-based antitubercular treatment were similar (median 0.83 mg/L IQR 0.59, 6.57 
and 0.86 mg/L IQR 0.61, 3.56, respectively; SR p= 0.125). Each child had at least one 
plasma efavirenz concentration measurement between 16 and 20 hours after dosing. The 
median MDI blood sampling time was 17.67 hours (IQR 17.45, 18.26). Median MDI 
concentrations were 1.24 mg/L (IQR 0.91, 7.38) and 1.23 mg/L (IQR 0.85, 4.18) during 
and after antitubercular treatment, respectively (SR p= 0.078). No significant differences 
were found in any of the PK parameters between TB/HIV co-infected group during 
antitubercular treatment with the control group (Table 3.1). Efavirenz half-life was 
correlated with higher efavirenz estimated Cmin and MDI concentrations (Spearman’s 
rho= 0.685, p< 0.001 and Spearman’s rho= 0.521, p< 0.001, respectively) and tended to 
be shorter during antitubercular treatment than after antitubercular treatment (Table 3.1). 
Nine (60%) and 8 (53%) of the children in the TB/HIV co-infected group had efavirenz 
estimated Cmin< 1 mg/L during and after rifampicin-based antitubercular treatment, 
respectively. Six children (40%) in the control group had estimated Cmin< 1 mg/L. 
Similarly, the MDI concentrations were < 1 mg/L in 6 children (40%) both during and 
after antitubercular treatment, whereas, 4 children (27%) in the control group had MDI 
concentrations < 1 mg/L. 
 
Table 3.1 Characteristics and PK measures in 15 TB/HIV co-infected children during and 
after antitubercular treatment and 15 HIV-infected children without TB in control group 
(EFV= efavirenz). Categorical variables are expressed as n (%); continuous variables are 
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1. Z-score weight for age is an application of statistical theory to describe how far a 
child’s weight is from the average weight of a child at the same age in the reference data 
(the National Centre for Health Statistics/WHO values). 
* p values were obtained from comparison of TB/HIV co-infected children during and 
after antitubercular treatment (SR test). 
**p values were obtained from the comparison between TB/HIV co-infected children 
when receiving antitubercular treatment and children in control group only receiving 
efavirenz-based cART alone (RS test). 
 
The distributions of efavirenz estimated Cmin and MDI concentrations are shown in 
Figure 3.1. Wide inter-individual variation in efavirenz concentrations was apparent, 
particularly during antitubercular treatment, and marked bimodality of the efavirenz 
concentrations was observed. High Cmin (> 4 mg/L) were estimated in 4 TB/HIV 
co-infected children during antitubercular treatment, and 2 children in the control group. 
Children with high estimated Cmin had prolonged half-life values in comparison to the 
TB/HIV co-infected Group Control Group 
Characteristics 
During TB treatment After TB treatment 
p 
value* On cART only 
p 
value** 
n 15 15  15  
Male 9 (60%) 9 (60%) 1.000 9 (60%) 1.000 
Median Age [years] 6.3 (4.3, 9.0) 7.1 (5.7, 9.2) <0.001 6.8 (5.4, 9.1) 0.633 
Median Weight [kg] 18.0 (15.7, 24.5) 20.5 (17.3, 24.8) 0.003 18.3 (17.3, 21.7) 0.756 
Median Height [cm] 109.4 (101.5, 123.7) 113.4 (105.6, 124.3) <0.001 110.0 (101.1, 115.0) 0.852 
Median EFV dose [mg/kg] 13.9 (12.3, 15.2) 14.0 (12.8, 14.5) 0.050 13.9 (13.7, 14.5) 0.950 
Median z-score Weight for age1 -1.10 (-1.63, -0.15) -0.72 (-1.23, -0.19) 0.470 -1.33 (-2.03, -1.19) 0.663 
PK Measures      
Median Cmin [mg/L] 0.83 (0.59, 6.57) 0.86 (0.61, 3.56) 0.125 1.18 (0.46, 1.70) 0.756 
Median MDI [mg/L] 1.24 (0.91, 7.38) 1.23 (0.85, 4.18) 0.078 1.58 (0.67, 2.20) 0.820 
Median Half life [hours] 11.71 (9.18, 17.29) 24.66 (12.60, 44.14) 0.156 13.13 (8.15, 19.69) 0.852 
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remaining children (median 33.35 hours IQR 17.29, 66.65 vs. 10.87 hours IQR 8.10, 
13.72; RS p= 0.001). Interestingly, amongst the 4 ‘slow metabolizers’ in TB/HIV 
co-infected group during antitubercular treatment, efavirenz concentrations were 
consistently decreased after antitubercular treatment with median changes of -2.64 mg/L 
(range -3.01, -2.01; SR p= 0.068) and -2.80 mg/L (range -3.20, -2.41; SR p= 0.068) in 
Cmin and MDI concentrations, respectively (Figure 3.1). In contrast, changes in median 
Cmin and MDI concentrations in the remaining patients were negligible (median change 
for Cmin 0.01 mg/L IQR -0.21, 0.29, SR p= 1.00; and for MDI concentration -0.06 mg/L 
IQR -0.23, 0.22; SR p= 0.722). 
 


























Figure 3.1 Distribution plot of efavirenz estimated Cmin concentrations and MDI 
concentrations. Solid lines indicate the respective Cmin and MDI during and after 
antitubercular treatment. 
A: TB/HIV co-infected children receiving rifampicin-based antitubercular treatment and 
efavirenz-based cART. 
B: The children included in “A” after completion of their antitubercular treatment and 
receiving efavirenz-based cART. 
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Efavirenz doses were adjusted in 5 children with low estimated Cmin and MDI 
concentrations (2 TB/HIV co-infected children and 3 in the control group). Efavirenz 
doses were increased by 100 mg in the 2 children during antitubercular treatment. 
Repeated estimated Cmin and MDI concentrations were above 1 mg/L after dose 
adjustment in both children. However, after changing back to standard doses on 
completion of antitubercular treatment, the estimated Cmin were lower than 1 mg/L in 
both children. Efavirenz doses were increased by 50 mg in the 3 children from the control 
group. The estimated Cmin and MDI concentrations were above 1 mg/L in 2 of the 3 
children after dose adjustment. 
 
Viral load results were available for 29 of the 30 children at least 6 months (6 had viral 
load results at 1 year) after initiating antiretroviral therapy. Twenty-two children (76%) 
with viral loads under the detectable limit of the assay (< 50 copies/mL) had significantly 
higher estimated Cmin than the remaining 7 children (median 1.22 mg/L IQR 0.67, 5.10 vs. 
0.46 mg/L IQR 0.30, 1.40, respectively; RS p= 0.022). These 7 children had viral load 
log10 values ranging from 2.40 to 4.23. Five of 7 (71%) with detectable viral loads had 
estimated Cmin< 1 mg/L compared to 9 of 22 (41%) of those with viral suppression 
(Chi-squared test, p= 0.159). 
 
3.3.2 Verification of Efavirenz Cmin Estimation 
The true efavirenz plasma Cmin concentrations were measured at 24 hours after the dose 
given the previous evening in 5 TB/HIV co-infected children and repeated in 3 of them 
after completion of antitubercular treatment. Estimated efavirenz plasma Cmin 
concentrations determined by extrapolation from the log-linear regression line of the 3 
concentration vs. time points at 24 hours after dosing and single MDI concentrations were 
compared with the true Cmin concentrations in these children (Table 3.2). The estimated 
Cmin for one child could not be calculated as he had an elevated efavirenz concentration at 
the third sampling point. The mean relative prediction error (bias) of estimated Cmin was 
-5.88% for the rest 7 samples, although a large relative imprecision (33.66%) was 
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concentrations, 3 (43%) had efavirenz true Cmin and estimated Cmin below 1 mg/L. One 
child had efavirenz estimated Cmin < 1 mg/L, but had normal true Cmin. For this individual, 
the true Cmin was similar to the concentration at last sampling at 19.58 hours after dosing 
(1.06 and 1.05 mg/L, respectively), indicating a flat elimination curve in this child. 
However, both concentrations were on the borderline of the minimum recommended 
concentration. The sensitivity and specificity for detecting sub-therapeutic efavirenz 
trough concentration using the estimation method were 100% and 75%, respectively. 
 
The concentrations at the second sampling point were used as the single MDI 
concentrations, with the sampling time ranging from 15.50 to 19.55 hours after efavirenz 
intake. The mean relative prediction error (bias) of using the single MDI concentrations 
was 23.78% with mean relative imprecision of 18.77%. The sensitivity and specificity of 
the single MDI concentrations were both 100%. The linear correlations between 
efavirenz estimated Cmin and single MDI concentrations with the true Cmin are shown in 
Figure 3.2. The goodness of fit (R2) values for estimated Cmin and single MDI sample 
with the true Cmin were 0.84 and 0.97, respectively. 
 
Table 3.2 Comparison between efavirenz estimated Cmin and single MDI concentrations 
with the true Cmin amongst 5 TB/HIV co-infected children (3 during and after 
antitubercular treatment and 2 during antitubercular treatment). 
 
Subject On/ off RIF Estimated Cmin  
(mg/L) 
True Cmin  
(mg/L) 
Single MDI Sample 
(mg/L) 
1 On 0.26 0.24 0.27 
1 Off - * 1.11 1.68 
2 On 0.49 0.43 0.51 
2 Off 0.78 0.54 0.84 
3 On 1.30 1.40 1.58 
3 Off 0.46 1.06 1.30 
4 On 1.87 2.91 3.13 
5 On 1.13 1.27 1.42 
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Figure 3.2 Linear correlations between efavirenz estimated Cmin and single MDI 
concentrations with true Cmin (solid line). The 90% confidence interval (CI) was indicated 
by the dashed lines. 
 
a) Correlation between estimated Cmin and true Cmin 
























b) Correlation between single MDI concentrations and true Cmin 

































It was found that co-administration of rifampicin-based antitubercular treatment did not 
significantly reduce the key efavirenz PK parameter, the estimated Cmin concentration. 
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and MDI concentrations was not significantly affected by rifampicin-based antitubercular 
treatment. Similarly, studies amongst South African adults receiving standard doses of 
efavirenz have failed to demonstrate significant reductions in efavirenz concentrations 
during compared to after rifampicin-based antitubercular therapy [Friedland et al. 2006; 
Cohen et al. 2009]. Although a study in 8 Spanish patients reported decreases in median 
efavirenz Cmax, Cmin and AUC of 24%, 18% and 10% respectively after 7 days of 
concomitant rifampicin, none of these differences were statistically significant 
[Lopez-Cortes et al. 2002]. Conversely, a recently published analysis found a 35% 
reduction (95% CI -56.2%, -2.1%) in efavirenz TDM sample concentrations amongst 339 
patients (17% on rifampicin) after adjustment for weight, ethnicity and concomitant 
zidovudine [Stöhr et al. 2008]. In this study, the half-life tended to be reduced during 
antitubercular treatment consistent with induction of efavirenz metabolism by rifampicin. 
However, this finding was not reflected in the closely similar median estimated Cmin and 
MDI concentrations during and after antitubercular treatment. Physiological changes in 
response to treatment, improved nutritional status and maturation (e.g. growth, weight 
gain and altered serum protein concentrations) affecting volume of distribution and drug 
disposition may have resulted in higher peak concentrations of efavirenz without apparent 
differences in the estimated Cmin and MDI concentrations. Furthermore, as no robust 
estimations of adherence to treatment were available, it cannot be excluded that there was 
improved adherence during antitubercular treatment given the wide variability in 
efavirenz concentrations. The time of the evening dose of efavirenz prior to PK sampling 
which could affect Cmin estimations and MDI concentrations was not directly observed by 
study investigators. The study was underpowered to detect relatively small differences in 
efavirenz PK parameters between TB/HIV co-infected group during antitubercular 
treatment and the control group. However, using parametric assumptions for the within 
subject comparison, 33 TB/HIV co-infected children are required to detect the mean 
reduction of 0.7 mg/L (26%) in efavirenz concentrations during antitubercular treatment 
(significance level= 0.05; 90% power; 20% drop-out rate). A larger study is warranted to 











Chapter 3 Efavirenz-Rifampicin PK Drug-Drug Interaction Study 
 45 
Wide inter-patient variation and bimodality were observed. Genetic polymorphisms could 
explain the high estimated Cmin in 6 children (20%). Exonic single nucleotide 
polymorphisms of CYP2B6 have been described and are associated with impaired 
metabolism and increased levels of efavirenz [Haas et al. 2004; Tsuchiya et al. 2004]. 
Some of these are more common amongst populations of African origin [Haas et al. 2004; 
Wang et al. 2006]. A weakness of this study is the lack of genetic information; however, 
genetic analysis was beyond the scope of this investigation. 
 
Contrary to expectation, 4 ‘slow metabolizers’ in the TB/HIV co-infected group had 
increased efavirenz concentrations during antitubercular treatment. A similar pattern was 
noted in 2 studies amongst South African adults [Friedland et al. 2006; Cohen et al. 
2009]. It is interesting to speculate that the consistently higher efavirenz concentrations 
during antitubercular treatment amongst the ‘slow metabolizers’ might be due to 
inhibition of an accessory metabolic pathway by isoniazid. In vitro studies have shown 
that isoniazid inhibits CYP3A4 and CYP2A6 amongst other enzymes [Wen et al. 2002]. 
Furthermore, a recent study suggests that functional polymorphisms in CYP3A4 and 
CYP2A6 are important determinants of efavirenz exposure in patients with limited 
CYP2B6 function [di Lulio et al. 2008]. To our knowledge, the effect of the combination 
of isoniazid and rifampicin on the activity of different CYP isoenzymes is poorly 
characterized. Even so, the inhibitory action of isoniazid on accessory pathways of 
efavirenz metabolism may moderate the effect of rifampicin-induced CYP2B6 activity on 
efavirenz concentrations. 
 
Although median body weight increased by 2.5 kg between the two sampling occasions, 
the doses of efavirenz were kept in line with the increased body weight. It was found a 
high proportion of children dosed correctly according to the manufacturer’s instructions 
had sub-therapeutic efavirenz estimated Cmin and MDI concentrations. In the Pediatric 
AIDS Clinical Trials Group (PACTG) 382 study [Starr et al. 1999], 22 of the 50 children 
receiving efavirenz (44%) had their daily doses of efavirenz increased based on 
pharmacokinetic assessment of the 24-hour AUC at 2 weeks after starting the study 
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than 1 mg/L (personal communication, Professor Coutney V. Fletcher, University of 
Colorado Health Sciences Center, Denver, CO, 2006). In this study the efavirenz doses 
given corresponded to, or were slightly higher, than the starting doses used in the PACTG 
382 study. The proportion of children with estimated minimum concentrations less than 1 
mg/L was greater than in PACTG 382. Children in this study tended to be younger (7.15± 
3.09 vs. 8.5± 3.3 years) than the children in the PACTG study. 
 
In keeping with adult studies showing that low efavirenz concentrations are associated 
with virological failure [Marzolini et al. 2001; González de Requena et al. 2004; Cohen et 
al. 2009], children in this study with virological failure had significantly lower efavirenz 
estimated Cmin than those children who had undetectable viral loads. Virological failure 
was observed in 5 of the 14 children (36%) had low efavirenz estimated Cmin (<1 mg/L), 
compared to 13% of those who had estimated Cmin> 1 mg/L. This study raises concern 
that many children may be under-dosed using the current guidelines. A non-linear mixed 
effect PK model describing efavirenz concentrations in 33 children from the Netherlands 
suggested that an adult efavirenz dose should be given to children weighing ≥ 25 kg, and 
that dose should be allometrically scaled a priori for other weight levels [ter Heine et al. 
2008]. Another study in 48 West African children observed that 19% children had 
efavirenz Cmin below the therapeutic concentration, and that children weighing less than 
15 kg were more likely to have sub-therapeutic concentrations. They recommended a 
higher dose of efavirenz (25 mg/kg) for children under 6 years of age, 15 mg/kg dose for 
children between 6- 10 years, and 10 mg/kg efavirenz dose for children between 10- 15 
years in order to optimize efavirenz Cmin concentrations [Hirt et al. 2009]. A study by 
Wintergerst et al. reported higher plasma efavirenz concentrations (median 2.8 mg/L; 8.8 
%< 1 mg/L) in 33 HIV-infected children (two thirds of whom were sampled 8 to 20 hours 
after the dose) than those observed in this study (median MDI concentration 1.4 mg/L; 
33%< 1 mg/L) amongst slightly younger children (median 6.75 years range 1.42, 14.75 vs. 
8.2 years range 2.1, 16.7) [Wintergerst et al. 2008]. A recent study in an older Thai 
paediatric population (median age 12.3 years range 3.1, 18.7) showed that efavirenz 
plasma concentrations were adequate in majority of Thai children (only 13% had 
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[Puthanakit et al. 2009]. Thus differences in the sampling strategies, study populations 
and age appear to contribute to the differences in the findings between studies. 
 
It is important to conduct pharmacokinetic studies in the relevant paediatric populations. 
Biochemical and physiological changes induced by the disease states may alter the 
pharmacokinetics of efavirenz in patients with TB/HIV co-infection. Furthermore, there 
are important age-related factors affecting pharmacokinetics [King et al. 2002; Saitoh et 
al. 2007]. As the true Cmin occurs in the evening, a simple method was introduced to 
estimate efavirenz Cmin in the out-patient clinics. The elimination rate constant was 
derived from a relatively narrow sampling range, compared with the long elimination 
half-life of efavirenz. However, the last sampling time for all 30 children was very close 
to 24 hours (median 18.7 hour, range 16.3, 20.8). 
 
The estimation method of efavirenz Cmin was more accuracy to predict 24-hour true Cmin 
than the single MDI concentrations, as 3 concentration points allowed to observe a 
decline in efavirenz concentrations during elimination phase. The current recommended 
minimum therapeutic concentration of efavirenz 24-hour Cmin was based on the results 
from studies using single MDI concentrations, which showed a better specificity for 
detecting sub-therapeutic efavirenz trough concentrations in this study. However, a lager 
samples are required to definitely validate the method. 
 
In conclusion, trough and MDI concentrations of efavirenz in children appeared not to be 
substantially different during vs. after rifampicin-based antitubercular treatment or during 
vs. control group without antitubercular treatment. Larger studies are needed to 
confidently define the effect of antitubercular treatment on efavirenz concentrations. A 
substantial proportion of South African children with and without concomitant 
antitubercular treatment have sub-therapeutic efavirenz concentrations despite being 
correctly dosed according to the manufacturer. The recommended efavirenz doses should 


















Effect of Rifampicin on Lopinavir and Ritonavir Pharmacokinetics in 




Rifampicin is a strong inducer of cytochrome P450 enzymes, notably CYP3A 
isoenzymes, and of P-glycoprotein. Lopinavir, a PI, is primarily metabolized by CYP3A 
isoenzymes and is also a substrate of P-glycoprotein [Lee et al. 1998; Vishnuvardhan et 
al. 2003]. Ritonavir is a potent inhibitor of CYP3A and P-glycoprotein [Koudriakova et 
al. 1998; Kumar et al. 1999; Eagling et al. 1997; Lee et al. 1998; Profit et al. 1999; 
Washington et al. 1998; Gutmann et al. 1999]. For this reason, ritonavir is co-formulated 
with lopinavir in a lopinavir: ritonavir ratio of 4:1 as Kaletra® (LPV/r) to maintain high 
plasma concentration of lopinavir throughout the dosing interval. Co-administration with 
rifampicin resulted in a 90 to 99% reduction in trough (Cmin) lopinavir concentrations in 
two studies in healthy adult volunteers [Bertz et al. 2000]. Therefore, co-administration of 
rifampicin and LPV/r is not recommended. 
 
A study in healthy adult volunteers [la Porte et al. 2004] showed that adjusted dose 
regimens of LPV/r with concomitant rifampicin resulted in acceptable peak and trough 
lopinavir concentrations. Trough concentrations were best preserved by adding ritonavir 
to LPV/r to give a lopinavir: ritonavir ratio of 1:1. 
 
LPV/r based cART is used in South African children who are aged between 6 months to 
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of MTCT. The objective of this study was to evaluate whether the approach of adjusted 
dose regimen of LPV/r (adding extra ritonavir to standard dose of LPV/r; lopinavir: 
ritonavir ratio 1:1) can be used to overcome the reduction effect of rifampicin-based 




A total of 30 children (aged from 6 months to 15 years) were enrolled: 15 TB/HIV 
co-infected children receiving LPV/r with additional ritonavir (lopinavir: ritonavir ratio 
1:1) as part of cART and concomitant rifampicin-based antitubercular treatment, and 15 
HIV-infected children without tuberculosis receiving LPV/r based cART. Lopinavir 230 
mg/m2/dose + ritonavir 57.5 mg/m2/dose (lopinavir: ritonavir ratio 4:1, Kaletra® liquid 
formulation) was given twice a day in combination with twice daily dual NRTIs to 
children in the control group, additional ritonavir 172.5 mg/m2/dose (lopinavir: ritonavir 
ratio 1:1) was given to children receiving antitubercular treatment. Doses calculated 
according to body surface area were rounded up to the nearest 0.1 mL. Children were 
recruited at three sites: the HIV Clinic at Red Cross Children’s Hospital, Cape Town; the 
Harriet Shezi Children’s Clinic, Chris Hani Baragwanath Hospital, Soweto; and Brooklyn 
Chest Hospital, Cape Town. Institutional approval of the study was granted by the 
research ethics committees of the University of Cape Town, Stellenbosch University and 
the University of the Witwatersrand. 
 
Exclusion criteria were: renal, hepatic, or intestinal disease (including malabsorption or 
diarrhoea); active opportunistic infections; recent exposure to drugs described to have PK 
interactions with lopinavir; or reported missed doses of LPV/r in the preceding 3 days. 
They were accompanied by a parent or legal guardian who provided written informed 
consent to participate in the study. Rifampicin-based antitubercular treatment regimens 
were administered in accordance with the National Tuberculosis Treatment Programme. 
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Co-infected children were on treatment for TB and HIV for at least 4 weeks before PK 
evaluation. Lopinavir and ritonavir concentrations were evaluated a second time in this 
group of children at least 4 weeks after completing antitubercular treatment and receiving 
standard doses of LPV/r. The children without TB were established on cART for at least 
4 weeks before lopinavir and ritonavir concentrations were measured. The exact time of 
the morning dose of lopinavir-ritonavir was recorded, and 8 blood samples were collected 
at 0 (pre-dose sample), 2, 3, 4, 5, 6, 8 and 12 hours after drug intake. 
 
4.2.3 Data Analysis 
Plasma concentrations of lopinavir and ritonavir were determined by LC/MS/MS. The 
detailed methods were described in the Materials and Methods Chapter (Section 2.1). 
WinNonlin version 4.1 (Pharsight Corp., Mountain View, CA) was used to characterize 
the PK parameters of lopinavir from concentration-time curves by non-compartmental 
analysis. The maximum concentration (Cmax) and the time to Cmax (Tmax) were determined 
directly from the concentration-time data. Lopinavir Cmin was the concentration measured 
at the 12-hour time point. Area under the curve (AUC0-12) was calculated at the steady 
state with a dosing interval of 12 hours (Tau= 12 hours). The terminal half-life was 
determined by linear regression of the elimination phase from the plasma 
concentration-time curve. 
 
4.2.4 Statistical Analysis 
Wilcoxon RS test and Wilcoxon matched-pairs SR test were used for independent groups 
and paired observations, respectively. A probability of ≤0.05 was considered statistically 




4.3.1 The Effect of Rifampicin on Lopinavir PK Measures  
The children’s general characteristics are summarized in Table 4.1. The co-administered 
NRTIs were stavudine plus lamivudine in 22 (73%) and lamivudine plus zidovudine in 8 
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ranging from 1.0 to 2.1 mL. The maximum total volume of LPV/r with additional 
ritonavir administered was 3.5 mL when receiving concomitant antitubercular treatment. 
Drug administration was observed by study nurses after pre-dose sampling, and no 
vomiting incident has been recorded shortly after drug intake.  
 
Full adherence to their antiretroviral therapy during the 3 days prior to PK evaluation was 
reported for all 30 participants. The median duration of antiretroviral treatment was 20 
weeks, ranging from 4-173 weeks. Twenty-eight children had viral load information up to 
6 months after initiation of antiretroviral treatment.  Twenty of 28 children (71%) had 
viral loads under the detectable limit of the assay (<50 copies/mL) after at least 6 months 
of antiretroviral therapy. Of the remaining 8 children, 4 from each group had viral load 
log10 values ranging from 2.54 to 4.72. Ten of 15 TB/HIV co-infected children had 
repeated PK sampling after antitubercular treatment. Two children during antitubercular 
treatment, two children after antitubercular treatment and 1 child without tuberculosis had 
slightly higher than normal (5 to 30 units/L) ALT concentrations (35 and 40, 35 and 43, 
and 42 units/L in the 2 groups respectively). However, they were all below 1.5 times of 
upper normal limit (UNL) of ALT normal range. The ALT concentrations after 
antitubercular treatment were not available for the 2 children with elevated ALT 
concentrations during antitubercular treatment (technique problems occurred on 1 sample, 
and the other child was lost to follow-up). The 2 children, whose ALT concentrations 
were abnormal after antitubercular treatment, had ALT concentrations within the normal 
range during antitubercular treatment. Five of the TB/HIV co-infected children (33%) 
were established on cART before they were treated for TB. None of the five developed 
elevated ALT concentrations during or after antitubercular treatment. 
 
The lopinavir PK measures are shown in Table 4.1, and the concentration-time curves are 
shown in Figure 4.1. Large inter-patient variability was observed. No significant 
differences were found between any of the PK measures during vs. after rifampicin-based 
antitubercular treatment in the 10 children who were sampled during and after 
antitubercular treatment, although Cmax tended to lower during antitubercular treatment 
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actual time at the 12-hour-sampling point was significantly earlier in TB/HIV co-infected 
children after antitubercular treatment than in those during treatment (median 11.50 hour 
IQR 10.38, 12.00 vs. 11.58 hour IQR 11.17, 12.00; SR p= 0.048), however, no significant 
difference was found between lopinavir Cmin during and after antitubercular treatment. 
Significant reductions in lopinavir Cmax (median 10.50 mg/L IQR 7.06, 14.30 vs. 14.20 
mg/L IQR 11.90, 23.50; RS p= 0.018) and in AUC0-12 (median 80.86 mg·h/L IQR 50.87, 
121.74 vs. 117.83 mg·h/L IQR 80.41, 176.08; RS p= 0.036), but not in lopinavir Cmin 
(median 3.94 mg/L IQR 2.26, 7.66 vs. 4.64 mg/L IQR 2.32, 10.40; RS p= 0.468), were 
observed in children during antitubercular treatment compared with children in the 
control group receiving standard dose of LPV/r without concomitant rifampicin. 
Statistical significant differences were not found in any of the lopinavir PK parameters 
between TB/HIV co-infected children after antitubercular treatment and children in the 
control group without TB. 
 
The median BSA was increased significantly after antitubercular treatment (p= 0.005), 
but lopinavir was dosed accordingly, resulting in no difference in lopinavir dose/BSA (p= 
0.508). Both groups had lopinavir doses slightly higher than the recommended dosage 
(230 mg/m2). All children but two had lopinavir Cmin above 1 mg/L. The two children 
with low lopinavir Cmin were receiving additional ritonavir with rifampicin-based 
antitubercular treatment, while their pre-dose sample concentrations were 2.17 and 4.29 
mg/L, the half-life of lopinavir in these children were substantially shorter (0.97 and 1.75 
hours) than that observed in any of the other children. One of these 2 children had a low 
dose of additional ritonavir due to a dosing error (49.5 vs. 172.5 mg/m2) when receiving 
concomitant rifampicin. Two children from the control group not receiving rifampicin 
had lopinavir pre-dose concentration below 1 mg/L, but normal Cmin concentrations. They 
were suspected to have missing doses prior to PK sampling. The results from Wilcoxon 
RS and SR tests remained unaffected after these 3 children were excluded from the 
analysis. All children after rifampicin-based antitubercular treatment had lopinavir Cmin 
and pre-dose concentration above 1 mg/L, including the two children who had lopinavir 
Cmin< 1 mg/L during antitubercular treatment. The half-life of lopinavir in these children 
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Table 4.1 General characteristics and lopinavir PK measures of children in TB/HIV 
co-infected group during and after antitubercular treatment and in control group. 
Categorical variables are expressed as n (%); continuous variables are summarized using 
median (IQR). (RIF=rifampicin; LPV= lopinavir) 
Characteristics 
During TB treatment 
(RIF and LPV/r = 1:1) 





(LPV/r = 4:1) 
p** 
value 
n 15 10 - 15 - 
Female 8 (53%) 7 (70%) 0.405 10 (67%) 0.456 
Median Age [months] 16 (14, 24) 25 (19, 31) 0.005 29 (22, 34) 0.004  
Median Weight [kg] 8.6 (7.8, 9.9) 11.0 (10.0, 12.6) 0.006 11.6 (10.5, 13.4) 0.002  
Median Height [cm] 77.0  (71.4, 79.0) 80.3 (79.0, 83.2) 0.006 82.5 (79, 87.9) 0.002  
Median BSA1 [m2] 0.42 (0.41, 0.46) 0.49 (0.47, 0.53) 0.005 0.51 (0.48, 0.55) 0.001  
Median LPV dose/BSA [mg/ m2] 291.9 (274.3, 308.6) 289.1 (285.8, 302.7) 0.508 265.2 (248.8, 289.3) 0.034  
Median z-score Weight for age -1.97 (-2.93, -0.98) -0.97 (-1.51, -0.4) 0.139 -1.00 (-1.85, -0.48) 0.085 
Lopinavir PK measures      
Median Tmax
2 (hour) 3.00 (2.00, 4.07) 3.54 (2.97, 5.00) 0.221 3.92 (2.78, 4.00) 0.467 
Median Cmax
3 (mg/L) 10.50 (7.06, 14.30) 14.44 (9.82, 16.76) 0.075 14.20 (11.90, 23.50) 0.018 
Median Cmin
4 (mg/L) 3.94 (2.26, 7.66) 8.52 (2.94, 10.78) 0.139 4.64 (2.32, 10.40) 0.468 
Median AUC0-12
5 (mg·h/L) 80.86 (50.87, 121.74) 114.95 (76.60, 160.54) 0.114 117.83 (80.41, 176.08) 0.036 
Median Cpre-dose
6 (mg/L) 5.20 (4.18, 9.30) 7.86 (5.54, 14.54) 0.386 8.12 (6.34, 13.00) 0.310 
Median Half life (hour) 7.58 (4.01, 16.61) 10.54 (4.08, 15.62) 0.575 4.86 (3.82, 8.29) 0.254 
1. BSA- body surface area 
2. Tmax- time to maximum concentration 
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4. Cmin- concentration at 12-hour point (the evening trough) 
5. AUC0-12- area under the curve to 12 hours 
6. Cpre-dose- Pre-dose concentration (the morning trough) 
* p values were obtained from comparison of 10 TB/HIV co-infected children during and 
after antitubercular treatment (SR test). 
** p values were obtained from comparison made between TB/HIV co-infected children 
during antitubercular treatment and the control group (RS test). 
 
Figure 4.1 Lopinavir concentration vs. time curves 
a) Lopinavir concentration vs. time curves during and after antitubercular treatment. The 
concentration-time curve for TB/HIV co-infected children receiving LPV/r with 
additional ritonavir (lopinavir: ritonavir ratio 1:1) and concomitant rifampicin is shown 
by the solid line; the curve for children in the same group after rifampicin-based 
antitubercular treatment, receiving standard doses of LPV/r (lopinavir: ritonavir ratio 4:1) 
is shown by the dashed line. The time points of the two occasions have been separated for 
clarity. Median concentrations and interquartile ranges are indicated at each time point. 
 







TB/HIV co-infected children during antitubercular treatment
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b) Lopinavir concentration vs. time curves during antitubercular treatment and for the 
control group. The concentration-time curve for TB/HIV co-infected children receiving 
LPV/r with additional ritonavir (lopinavir: ritonavir ratio 1:1) and concomitant rifampicin 
is shown by the solid line; the curve for children in control group without tuberculosis is 
shown by the dashed line. The time points of the two groups have been separated for 
clarity. Median concentrations and interquartile ranges are indicated at each time point. 
 







TB/HIV co-infected children during antitubercular treatment




















c) Lopinavir concentration vs. time curves after antitubercular treatment and for the 
control group. The concentration-time curve for TB/HIV co-infected children after 
antitubercular treatment is shown by the solid line; the curve for children in control group 
without tuberculosis is shown by the dashed line. Children in both groups were receiving 
standard doses of LPV/r (lopinavir: ritonavir ratio 4:1). The time points of the two groups 
have been separated for clarity. Median concentrations and interquartile ranges are 
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TB/HIV co-infected children after antitubercular treatment




















4.3.2 Evaluation of Ritonavir Plasma Concentrations and PK Measures 
Ritonavir plasma concentrations were analyzed simultaneously with lopinavir 
concentrations. The median ritonavir plasma concentration was 0.42 mg/L (IQR 0.20, 
0.88). As a result of the increased doses of ritonavir (lopinavir: ritonavir ratio 1:1) in 
TB/HIV co-infected children during antitubercular treatment, all ritonavir PK parameters 
except the half-life and Tmax were significantly higher when compared to those after 
antitubercular treatment and to those in control group (Table 4.2; Figure 4.2). The median 
ratio of adjusted lopinavir: ritonavir during antitubercular treatment was 1.00 (IQR 0.95, 
1.00). One child had a low dose of additional ritonavir due to a dosing error (49.5 vs. 
172.5 mg/m2) (Section 4.3.1), resulting in lower ritonavir plasma concentrations of this 
child (median 0.40 mg/L IQR 0.18, 0.77 and 1.11 mg/L IQR 0.42, 2.39, respectively; p= 
0.015). The statistical differences between groups remained unaffected after this child 
together with 2 children from the control group, who were suspected to have missing 
doses prior to PK sampling (Section 4.3.1) were excluded from analysis. After resuming 
standard doses of LPV/r, no statistically significant differences were found in any of the 
ritonavir PK parameters between TB/HIV co-infected children after antitubercular 
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Ritonavir Cmin, AUC0-12 and half-life were correlated with lopinavir Cmin, AUC0-12 and 
half-life (spearman’s rho= 0.679, p< 0.001; spearman’s rho= 0.461, p= 0.003; and 
spearman’s rho= 0.539, p< 0.001 for Cmin, AUC0-12 and half-life, respectively). 
 
Table 4.2 Ritonavir PK measures for children in the TB/HIV co-infected group during 
and after antitubercular treatment and in the control group. Continuous variables are 
summarized using median (IQR). (RIF= rifampicin; RTV= ritonavir) 
 
Ritonavir PK measures 
During TB treatment 
(RIF and LPV/r = 1:1) 





(LPV/r = 4:1) 
p 
value** 
n 15 10 - 15 - 
Median RTV dose/BSA [mg/ m2] 301.3 (285.6, 308.6) 72.3 (71.5, 75.7) 0.005 66.3 (62.2, 72.3) <0.001 
Median Tmax
1 (hour) 2.05 (2.00, 3.00) 3.54 (2.02, 5.00) 0.059 3.92 (2.75, 4.00) 0.026 
Median Cmax
2 (mg/L) 2.32 (1.56. 4.99) 0.54 (0.39, 0.87) 0.009 0.61 (0.33, 0.93) 0.001 
Median Cmin
3 (mg/L) 0.22 (0.11, 0.85) 0.15 (0.06, 0.22) 0.037 0.11 (0.05, 0.17) 0.027 
Median AUC0-12
4 (mg·h/L) 9.45 (5.17, 27.03) 4.04 (2.53, 5.18) 0.009 3.97 (1.84, 5.36) 0.003 
Median Cpre-dose
5 (mg/L) 0.68 (0.19, 2.33) 0.26 (0.15, 0.40) 0.005 0.19 (0.09, 0.28) 0.011 
Median Half life (hour) 3.13 (2.31, 4.50) 3.53 (3.27, 4.26) 0.441 3.72 (2.85, 4.54) 0.178 
 
1. Tmax- time to maximum concentration 
2. Cmax- maximum concentration 
3. Cmin- concentration at 12-hour point (the evening trough) 
4. AUC0-12- area under the curve to 12 hours 
5. Cpre-dose- Pre-dose concentration (the morning trough) 
* p values were obtained from comparison of 10 TB/HIV co-infected children during and 
after antitubercular treatment (SR test). 
** p values were obtained from comparison made between TB/HIV co-infected children 
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Figure 4.2 Ritonavir concentration vs. time curves 
a) Ritonavir concentration vs. time curves during and after antitubercular treatment. The 
concentration-time curve for TB/HIV co-infected children receiving LPV/r with 
additional ritonavir (lopinavir: ritonavir ratio 1:1) and concomitant rifampicin is shown 
by the solid line; the curve for children in the same group after rifampicin-based 
antitubercular treatment, receiving standard doses of LPV/r (lopinavir: ritonavir ratio 4:1) 
is shown by the dashed line. The time points of the two occasions have been separated for 
clarity. Median concentrations and interquartile ranges are indicated at each time point. 
 












TB/HIV co-infected children during antitubercular treatment




















b) Ritonavir concentration vs. time curves during antitubercular treatment and for the 
control group. The concentration-time curve for TB/HIV co-infected children receiving 
LPV/r with additional ritonavir (lopinavir: ritonavir ratio 1:1) and concomitant rifampicin 
is shown by the solid line; the curve for children in control group without tuberculosis is 
shown by the dashed line. The time points of the two groups have been separated for 
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TB/HIV co-infected children during antitubercular treatment



















c) Ritonavir concentration vs. time curve after antitubercular treatment and for the control 
group. The concentration-time curve for TB/HIV co-infected children after antitubercular 
treatment is shown by the solid line; the curve for children in control group without 
tuberculosis is shown by the dashed line. Children in both groups were receiving standard 
doses of LPV/r (lopinavir: ritonavir ratio 4:1). The time points of the two groups have 
been separated for clarity. Median concentrations and interquartile ranges are indicated at 
each time point. 
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To our knowledge, this is the first paediatric study to evaluate lopinavir and ritonavir 
pharmacokinetics and the drug-drug interaction between an adjusted dose regimen of 
LPV/r and rifampicin in a TB/HIV co-infected population. Although the median lopinavir 
Cmax, Cmin and AUC0-12 were reduced by 27%, 54% and 30%, respectively, in children 
receiving additional ritonavir during antitubercular treatment compared to those in the 
same children on standard doses of LPV/r after antitubercular treatment, the differences 
failed to reach statistical significance. The within group comparison allowed us to 
compare paired observations which would have a lower variability in PI concentrations 
than the inter-individual variability between groups [Guiard-Schmid et al. 2003]. 
Unfortunately, the power of the within group comparison was restricted by the high 
drop-out rate (33%). Significant reductions in the median lopinavir Cmax and AUC0-12 
were found in children receiving additional ritonavir with rifampicin when compared to 
the control group, despite higher lopinavir doses in the children receiving antitubercular 
treatment. Previous studies have shown that the reduced lopinavir exposure was 
associated with the younger age [Verweel et al. 2007; Chadwick et al. 2008; Chadwick et 
al. 2009]. In this study, the younger age of children in TB/HIV co-infected group than 
those in the control group and other differences between the 2 groups (for example, 
co-infection with TB and disease states) may have impact on the statistical differences. 
However, the key parameter of lopinavir PK, Cmin, was not significantly different in the 
between group comparison. 
 
Lopinavir presented kinetics that are consistent with circadian rhythm. Although 
lopinavir Cmin (the evening trough) was 34% lower than the pre-dose concentration (the 
morning trough), 38 of total 40 (95%) lopinavir Cmin concentrations were above the 
recommended minimum therapeutic concentration (1 mg/L) [la Porte et al. 2006; 
www.hivpharmacology.com]. In contrast with a previous report [Verweel et al. 2007], a 
correlation was not found between lopinavir plasma concentrations and age (Spearman’s 
rho= -0.194, p= 0.353; n= 25, children after antitubercular treatment plus control group). 
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study (median 286.4 mg/m2 range 238.8, 339.0 vs. median 227 mg/m2 range 189, 254), 
and children in this study was younger (median age 2.3 years range 0.8, 3.9 vs. median 
5.6 years range 0.4, 13.2). 
 
A safety and efficacy paediatric study [Sáez-Llorens et al. 2003] demonstrated that LPV/r 
(lopinavir: ritonavir ratio 4:1) at a higher dose of 300/75 mg/m2 twice daily is 
well-tolerated in children. Only 1 in 100 children were discontinued due to study 
drug-related adverse events. In this study, slightly elevated ALT levels were observed in 
the same number of children during and after antitubercular treatment. None of the 
children had their treatment interrupted due to elevations of ALT. In contrast, 38% of 
adult healthy normal volunteers were withdrawn as a result of adverse events, and 28% 
had raised liver enzyme concentrations during treatment with adjusted doses of lopinavir 
and ritonavir together with rifampicin [la Porte et al. 2004]. It was found that the 
combination of additional ritonavir (lopinavir: ritonavir ratio 1:1) with rifampicin was 
generally well tolerated in children. However, further investigation regarding toxicity and 
efficacy of LPV/r with extra ritonavir and rifampicin-based antitubercular treatment 
needs to be carried out. 
 
Rifabutin can be used in antitubercular treatment instead of rifampicin in patients on 
LPV/r-based HAART, as rifabutin does not affect lopinavir concentrations [Centers for 
Disease Control, 2004]. This approach is not a feasible option for most tuberculosis 
control programs in developing countries as rifabutin is currently prohibitively expensive. 
There is no suitable rifabutin formulation for pediatric practice, which precludes the use 
of rifabutin in very young children. Furthermore, in high burden countries tuberculosis 
control programs rely on standard treatment regimens in fixed dose combinations 
administered by nurses. 
 
For ritonavir, a less than proportional increase in ritonavir plasma concentrations were 
achieved during antitubercular treatment with adjusted doses of LPV/r (lopinavir: 
ritonavir ratio 1:1) compared to those achieved with standard doses of LPV/r (lopinavir: 
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considerably higher ritonavir concentrations during antitubercular treatment. There are 
important age-related factors affecting pharmacokinetics, of particular relevance to 
lopinavir and ritonavir is the activity of cytochrome P450 enzyme system [King et al. 
2002], may explain the inconsistency in the findings between the 2 studies. Disease states 
could also alter the PK of ARV drugs in patients with TB/HIV co-infection, for example 
by altering the concentrations of the drug-transporting proteins. Therefore, it is important 
to conduct PK studies in the relevant paediatric diseased population rather than to 
extrapolate from adults, particularly from healthy volunteers. 
 
A positive relationship was found between the half-life of ritonavir and lopinavir, 
indicating similar systematic elimination for ritonavir and lopinavir. This study also 
revealed the positive associations of Cmin and AUC0-12 between ritonavir and lopinavir. 
This is in keeping with the findings from previous adult study [Guiard-Schmid et al. 
2003], suggesting high plasma concentration of ritonavir accentuates its enhancement 
effect on lopinavir. 
 
The main limitations of this study are small sample size and the high drop-out rate in 
children after antitubercular treatment due to family relocating. Plasma concentrations of 
PIs display large inter-patient variability, as illustrated by the coefficient of variation. The 
inter-individual viability for lopinavir Cmin were 86.2% and 68.2% during and after 
antitubercular treatment in TB/HIV co-infected group and 111.4% for the control group. 
For ritonavir, the inter-individual viability of Cmin concentrations was 159.8% and 87.0% 
during and after antitubercular treatment and 108.3% for the control group. This is 
another factor which limits the power of this study. However it is difficult to recruit large 
numbers of paediatric patients for PK studies. 
 
In conclusion, this study in children confirmed the findings of a previous adult healthy 
volunteer study [la Porte et al. 2004] that the reduction of lopinavir trough concentrations 
caused by rifampicin can be attenuated by adding extra ritonavir to LPV/r (lopinavir: 
ritonavir ratio 1:1). This adjusted dose regimen of LPV/r achieved adequate trough 
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with rifampicin-based antitubercular treatment. However, due to the large inter-patient 
variability observed, TDM should be considered for children receiving concomitant 
rifampicin for optimal dosing. Hepatic ALT levels should also be monitored regularly as 
hepatotoxicity is a concern when rifampicin-based antitubercular treatment is used with 







































The Use of Dried Blood Spots as an Alternative Method to Plasma for 




As the accessibility to cART in developing countries increases, TDM is recommended to 
optimize ARV efficacy and to reduce toxicity of the treatment for HIV-infection [Back et 
al. 2002; Gerber et al. 2003; Boffito et al. 2005; Rendón et al. 2005]. Serum and plasma 
are the common matrices for routine TDM of NNRTI and PI in patient samples. 
Conventional methods using plasma or serum samples require expensive sample 
collection, processing techniques, storage and transportation conditions which are 
difficult or unavailable in resource-limited settings. Furthermore, the volume of blood 
required should be minimized for studies in children. 
 
DBS method has been used as an alternative to plasma for diagnosis of HIV-1 infection 
[Cassol et al. 1991; Cassol et al. 1992; Jacob et al. 2008], HIV-1 antibody testing 
[Solomon et al. 2002], HIV-1 drug resistance genotyping [Youngpairoj et al. 2008], 
CD4+ lymphocyte counts [Mwaba et al. 2003], and viral load measurement [Mwaba et al. 
2003; Brambilla et al. 2003]. Koal et al. [Koal et al. 2005] described a robust LC/MS/MS 
method for multicomponent analysis of PI and NNRTI drugs in DBS and showed 
concentrations correlated well between DBS and plasma. However, there is no data to 
support the use of a DBS method in paediatric PK study and in TDM practice. In this 
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between DBS and plasma concentrations were evaluated for efavirenz, lopinavir and 
ritonavir. The relatively large number of samples evaluated allowed good definition of 
variability in the findings between samples. Storage conditions, patient characteristics 
and treatment factors which may affect the stability and DBS/plasma correlations of 
efavirenz, lopinavir and ritonavir (key components of cART in South African children) 
were also evaluated. 
 
5.2 Methods 
5.2.1 DBS Sample Preparation and Assay 
DBS samples were obtained from efavirenz and lopinavir-ritonavir studies during plasma 
sampling. Exactly 50 µL aliquots from heparinized whole blood samples were spotted 
within 30 minutes after sampling onto 903 TFN filter paper cards with pre-marked circles 
(Munktell, Niederschlag, Germany) (Figure 5.1). The cards were dried at room 
temperature for 2 hours and stored in sealed plastic bags with desiccant at 4 ºC. The 
concentrations of efavirenz, lopinavir and ritonavir in DBS samples were determined 
simultaneously by validated LC/MS/MS methods. The detailed procedures were 
described in the Materials and Methods Chapter (Section 2.2). 
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5.2.2 Statistical Analysis 
Stata version 10.0 (Stata Corp., College Station, TX) was used to compute summary 
statistics. Spearman rank correlation test was used to determine the correlation between 
two variables in nonparametric data. Wilcoxon matched-pairs SR test and Wilcoxon RS 
test were used to compare paired and unpaired observations for skewed data, respectively. 
One-way Analysis of Variance (ANOVA) followed by Bonferroni’s correction was used 
to compare the mean DBS/plasma ratios at each time point for lopinavir and ritonavir.  
 
Variables of interest were individually tested in the first instance for associations with 
DBS/plasma ratios by univariate analyses. Variables with p values < 0.2 were included in 
the multivariate analysis to determine the overall effects. The appropriate model of 
multivariate analysis was chosen based on the Wald Chi squared values. 
 
A probability of ≤ 0.05 was considered statistically significant for all tests. 
 
5.3 Results 
5.3.1 Patient Samples 
A total of 135 patient samples containing efavirenz as part of cART were analyzed, in 
which 45 samples contained rifampicin; 45 samples were from the same children after 
completion of rifampicin-based antitubercular treatment and 45 were from children 
without TB. 
 
Of the 320 samples containing lopinavir and ritonavir that were analyzed, 120 samples 
were obtained from children receiving adjusted doses of LPV/r in a ratio of 
lopinavir:ritonavir= 1:1 with concomitant rifampicin, 80 samples were from the same 
children after completion of antitubercular treatment, receiving standard doses of LPV/r 
and 120 samples were from children without TB, receiving standard doses of LPV/r. Two 
samples had both plasma and DBS lopinavir and ritonavir concentrations below LLOQ. 
Another 3 samples had ritonavir DBS concentrations below LLOQ. Samples with 
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5.3.2 Log/log Linear Correlation between DBS and Plasma 
Figure 5.2 shows the log/log linear correlation (90% CI) between DBS and plasma 
concentrations. There were very strong linear correlations for all 3 drugs: efavirenz (p< 
0.001, spearman’s rho= 0.963; slope= 1.027); lopinavir (p< 0.001, spearman’s rho= 0.860; 
slope= 0.931) and ritonavir (p< 0.001, spearman’s rho= 0.932; slope= 0.914). Although 
the correlation was reduced during antitubercular treatment for lopinavir (spearman’s 
rho= 0.778 vs. 0.863, n= 120 vs. 200), concomitant antitubercular treatment had little 
effect on the linear correlation of efavirenz and ritonavir (spearman’s rho= 0.944 vs. 
0.962, n= 45 vs. 90; spearman’s rho= 0.918 vs. 0.908, n= 120 vs. 200). 
 
Figure 5.2 The 10-based logarithms of DBS vs. plasma concentrations with linear 
correlation line (solid line) and 90% confidence interval (dashed line). 
 
Efavirenz
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Lopinavir





























5.3.3 Distribution of ARV Drugs between Plasma and Whole Blood 
The DBS/plasma drug concentration ratios are summarized in Table 5.1. The 
DBS/plasma ratios with and without concomitant antitubercular treatment were compared 
within the same group of children (during vs. after antitubercular treatment; SR test), and 
between children with and without TB (after antitubercular treatment vs. controls without 
TB; RS test). The DBS/Plasma ratios during and after antitubercular treatment were not 
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lopinavir and ritonavir, respectively). However, significant differences in DBS/plasma 
ratios were found when TB/HIV co-infected children after antitubercular treatment were 
compared with children in control group without TB (p= 0.004, p< 0.001 and p< 0.001, 
for efavirenz, lopinavir and ritonavir, respectively). 
 
Univariate and multivariate analyses were used to identify factors, including ALB, HB, 
patient group differences (TB/HIV co-infected group and the control group), and the 
presence of concomitant rifampicin-based antitubercular treatment, which might affect 
the DBS/plasma ratios. In univariate analyses, efavirenz and lopinavir DBS/plasma ratios 
were not affected by ALB levels, whereas HB had no effect on ritonavir ratios (p> 0.2). 
Multivariate analyses showed that HB was negatively correlated with efavirenz 
DBS/plasma ratios (coefficient= -0.101; 95% CI -0.138, -0.065; p< 0.0001). Patient 
group differences rather than presence of rifampicin-containing antitubercular treatment 
also had significant effect on efavirenz ratios: co-infection with TB was associated with a 
14.3% increase in the efavirenz ratio (coefficient= 0.143; 95% CI 0.046, 0.240; p= 0.004). 
Whereas, presence of rifampicin was associated with 12.0% and 32.3% reductions in 
lopinavir and ritonavir DBS/plasma ratios, respectively (for lopinavir coefficient= -0.120; 
95% CI -0.181, -0.059; p< 0.0001 and for ritonavir coefficient= -0.323; 95% CI -0.410, 
-0.237; p< 0.0001). HB and ALB levels did not show significant associations with 
DBS/plasma concentration ratios in multivariate analyses for lopinavir and ritonavir, 
respectively. Effects of each co-variant on efavirenz, lopinavir and ritonavir DBS/plasma 
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Table 5.1 Median (IQR) DBS/plasma ratios for efavirenz, lopinavir and ritonavir. 
 
 
Efavirenz Lopinavir Ritonavir 
N 45 120 120 TB/HIV 
During TB treatment Median ratio (IQR) 0.98 (0.87, 1.17) 0.79 (0.61, 1.03) 1.07 (0.55, 1.28) 
N 45 80 80 TB/HIV 
After TB treatment Median ratio (IQR) 0.97 (0.86, 1.13) 0.79 (0.70, 1.07) 1.16 (1.03, 1.31) 
N 45 120 120 HIV control 
Without TB treatment Median ratio (IQR) 0.85 (0.73, 0.93) 0.67 (0.53, 0.82) 0.94 (0.61, 1.08) 
N 135 320 320 
All Subjects 
Median ratio (IQR) 0.93 (0.83, 1.08) 0.73 (0.61, 0.90) 1.05 (0.74, 1.21) 
 
Table 5.2 The effects of each co-variant on DBS/plasma concentration ratios of efavirenz, 
lopinavir and ritonavir are summarized using coefficients (95% CI). Wald Chi squared 
(Wald Chi2) values of the final multivariate models are also indicated. 
Factors Efavirenz Lopinavir Ritonavir 
HB 
-0.101 (-0.138, -0.065) 
p< 0.0001 
-0.046 (-0.098, 0.006) 
p= 0.086 
-* 
ALB -* -* 
-0.007 (-0.026, 0.012) 
p= 0.443 
Rifampicin 
-0.048 (-0.110, 0.015) 
p= 0.137 
-0.120 (-0.181, -0.059) 
p< 0.0001 




0.143 (0.046, 0.240) 
p= 0.004 
0.133 (-0.011, 0.277) 
p= 0.071 




 value 42.53 25.85 67.81 
* indicates co-variant which had p> 0.2 in univariate analyses and excluded from 
multivariate analysis models 
 
5.3.4 Comparison of PK Measures Between Plasma and DBS 
Efavirenz DBS and plasma MDI concentrations were very similar (median 1.27 IQR 0.82, 
2.61 vs. 1.34 IQR 0.90, 2.49; p= 0.708, respectively). Efavirenz estimated Cmin 
concentrations were also closely similar between DBS and plasma samples (median 1.01 










Chapter 5 The Use of DBS Method 
 71 
(k) values of the log-linear regression lines were comparable between plasma and DBS 
methods (k= -0.11 and k= -0.12, respectively) (Figure 5.3 a I). PK parameters of 
lopinavir and ritonavir were compared between plasma and DBS samples in Table 5.3. In 
keeping with the finding that the median lopinavir concentration was 27% lower in DBS 
than in plasma samples (Table 5.1), lopinavir Cmax and AUC0-12 were reduced by  
29.84% (p= 0.008) and 24.88% (p= 0.048) in DBS, respectively. Lopinavir Cmin and 
pre-dose concentrations were 16.60% and 16.10% lower in DBS samples, however, due 
to wide variability, statistically significant differences were not described. Ritonavir PK 
measures were comparable between plasma and DBS (Table 5.3; Figure 5.3 b I and c I). 
 
DBS/plasma ratios for these 3 drugs were not affected by the time interval after dose. The 
plot of DBS/plasma ratio against sampling time after drug intake is shown in Figure 5.3 II. 
Best fit linear regression line was used to illustrate the trend of DBS/plasma ratio changes 
over elimination phase for efavirenz. The slope of the best fit line was -0.012 with 
insignificant deviation from zero (p= 0.081). Although there were no significant 
differences in median DBS/plasma ratio at each time point for lopinavir and ritonavir (p= 
0.989 and p= 0.992, respectively; one-way ANOVA), median lopinavir DBS/plasma 
concentration ratios tended to be lower at 3- 5 hours than those at pre-dose and 12 hours 
after dose intake. 
 
Efavirenz had the lowest inter- and intra-individual variability in DBS/plasma 
concentration ratios amongst these 3 drugs. The inter- and intra-individual variability for 
efavirenz, lopinavir and ritonavir were 21% and 8.6%, 34% and 10.8%, and 33% and 
14.2%, respectively. The inter-individual viability of TB/HIV co-infected children during 
antitubercular treatment were 21.5, 36.3% and 41.0%, whereas, the viability were 
reduced in the same group of children after antitubercular treatment (17.8%, 31.8 and 
16.7% for efavirenz, lopinavir and ritonavir, respectively). The viability of efavirenz, 
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Table 5.3 Comparison of lopinavir and ritonavir PK measures between plasma and DBS. 
Continuous variables are summarized using median (IQR). The differences of PK 
measures between DBS and plasma are expressed in absolute percentage values. 
Lopinavir Ritonavir 
PK Measures 










































































(2.49, 4.61) 5.71% 0.901 
 
1. Tmax- time to maximum concentration 
2. Cmax- maximum concentration 
3. Cmin- concentration at 12-hour point 
4. AUC0-12- area under the curve to 12 hours 
5. Cpre-dose- Pre-dose concentration 
 
Figure 5.3 Plasma and DBS concentration vs. time curves, and plots of DBS/plasma ratio 
against sampling time after drug intake. 
a) Efavirenz 
(I) The scatter plot of efavirenz plasma (■) and DBS (▲) concentrations. The plasma 
log-linear regression line is indicated by solid line, and the DBS log-linear regression line 
is indicated by dash line. 
(II) Efavirenz DBS/plasma ratios vs. time interval after drug intake. The best fit linear 
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(I) Lopinavir DBS and plasma concentration vs. time curves. The concentration-time 
curve for plasma is shown by the solid line; the DBS concentration-time curve is shown 
by the dashed line. The time points of the two methods have been separated for clarity. 
Median (IQR) concentrations are indicated at each time point. 
(II) Lopinavir DBS/plasma ratios vs. time interval after drug intake. The median (IQR) of 
DBS/plasma ratios at each time point is indicated and connected by solid line. 
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c) Ritonavir  
(I) Ritonavir DBS and plasma concentration vs. time curves. The plasma 
concentration-time curve is shown by the solid line; the DBS concentration-time curve is 
shown by the dashed line. The time points of the two methods have been separated for 
clarity. Median (IQR) concentrations are indicated at each time point. 
(II) Ritonavir DBS/plasma ratios vs. time interval after drug intake. The median (IQR) of 
DBS/plasma ratios at each time point is indicated and connected by solid line. 
 














































5.3.5 Stabilities of ARV Drugs in DBS Samples 
The stabilities of efavirenz, lopinavir and ritonavir in DBS samples under various 
conditions are shown in Figure 5.4. All 3 drugs showed good stabilities at 37ºC for 7 days, 
under the high heat setting of a hair drier for 3 minutes, as well as exposure to sunlight 
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Figure 5.4 The stabilities of efavirenz, lopinavir and ritonavir in DBS samples under 
various conditions. 

























































































































































































































As ARV plasma concentrations are associated with virological response and development 
of toxicity, it is critical to maintain drug concentrations within a therapeutic range in 
order to achieve long-term efficacy from cART. TDM is recommended to identify toxic 
levels of NNRTIs and subtherapeutic concentrations of PIs to reach optimal 
individualized dosing [Rendón et al. 2005]. Despite the fact that HIV and AIDS 
pandemic occurs primarily in less developed countries of the globe, the TDM service is 
seldom available in these regions as it requires expensive processing techniques, storage 
and transportation conditions. A previous study [Koal et al. 2005] evaluated 70 samples 
containing total of 5 ARV drugs using plasma and DBS methods, and reported that 
concentrations correlated well between plasma and DBS in adults. In this study, the 
correlations between DBS and plasma concentrations were defined for efavirenz, 
lopinavir and ritonavir in children and the factors that affecting the correlations were also 
identified. 
 
In this study, efavirenz and ritonavir showed strong log/log linear correlations between 
DBS and plasma concentrations. The distribution between whole blood and plasma was 
close to a 1:1 ratio for efavirenz and ritonavir. And their PK measures calculated from 
DBS concentrations were also comparable with those calculated from plasma 
concentrations. However, the median lopinavir concentration was 27% (IQR 39%, 10%) 
lower in DBS in comparison to plasma samples, which is in keeping with the findings 
from the previous study [Koal et al. 2005]. It was also found that differences between 
DBS and plasma concentrations tended to be larger at lopinavir Cmax than those at trough 
concentrations. The differences in extraction efficacy is unlikely to be the cause of 
unequal drug distribution between plasma and red blood cells, as the extraction method 
was standardised and carried out at all times. Protein binding may play an important role 
in the drug distribution, however further investigation is needed. Moreover, building 
compartmental population models could be a useful tool to elucidate the mechanism of 
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Multivariate analyses indicated a significant negative correlation between efavirenz 
DBS/plasma concentration ratios with HB concentrations. This could be because HB and 
ALB concentrations were correlated (spearman’s rho= 0.364, p= 0.0001), and higher 
ALB concentrations are expected to be associated with increased efavirenz plasma 
concentrations and consequently with decreased DBS/plasmas ratios, as 99% of efavirenz 
in plasma is bound to ALB. However, a correlation was not found between DBS/plasma 
ratios and ALB concentrations. This may be due to missing ALB concentrations in some 
instances: there were 129 vs. 114 observations for HB and ALB, respectively. 
Rifampicin-based antitubercular treatment did not have a significant impact on efavirenz 
DBS/plasma concentration ratios. However, the presence of rifampicin-based 
antitubercular treatment was significantly associated with reduced lopinavir and ritonavir 
DBS/plasma concentration ratios. One explanation is that as an inducer of 
energy-dependent drug efflux proteins, the presence of rifampicin could cause pumping 
free drugs out of cells, resulting in reduced intracellular concentrations. However as red 
blood cells, which make up the majority of cells in the DBS samples, are not expected to 
have active transmembrane efflux pumps, a more likely explanation is that lopinavir and 
ritonavir are bound predominantly to AAG [Denissen et al. 1997], which is an acute 
phase reactant and is elevated in many acute and chronic infections. It is likely that the 
TB/HIV co-infected children had higher AAG concentrations (and consequently lower 
DBS/plasma concentration ratios) at the first PK assessment during antitubercular 
treatment than they had after antitubercular treatment. However, AAG concentrations 
were not determined, which is one of the limitations in this study. 
 
Antiretroviral drugs showed good stabilities in DBS samples at high temperature for up to 
7 days and under exposure to sunlight for up to 2 hours which make the requirements for 
storage and transportation less stringent. DBS samples can be dried using a hair drier on a 
high heat setting for 3 minutes which significantly shortens the drying period. The DBS 
method is also cost-effective as it simplifies sample collection/ preparation procedure and 
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method, which could be sampled from a finger prick and may make TDM and PK studies 
more convenient for study participants especially for children. 
 
In summary, strong log/log linear correlations between DBS and plasma, low 
intra-individual variability in DBS/plasma concentration ratios as well as less stringent 
sample collection and storage support the use of DBS as a field-friendly method in 
research and TDM practice for efavirenz, lopinavir and ritonavir. However, the pre-dose 
concentrations of lopinavir in DBS samples need to be increased by 16% when used to 
predict plasma concentrations in routine TDM samples. Furthermore, the frequently 
co-administered rifampicin may contribute to even larger variation between DBS and 
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Plasma concentrations of efavirenz and lopinavir have been associated with treatment 
efficacy [Marzolini et al. 2001; Csajka et al. 2003; Cohen et al. 2009; Masquelier et al. 
2002]. TDM may be applied to ensure plasma concentrations of these ARV drugs fall 
into their therapeutic ranges. However, as the target of efavirenz and lopinavir is within 
HIV-infected cells, measurement of intracellular concentrations of efavirenz and 
lopinavir could provide understanding of drug exposure at the action site. Furthermore, 
P-gp and MRP are transmembrane efflux proteins, which share overlapping substrate 
specificity with CYP3A4. Co-administration of the inhibitor/inducer of these drug efflux 
proteins may alter the intracellular accumulation of efavirenz and lopinavir. 
 
Studies have shown that efavirenz is a substrate for P-gp [Chandler et al. 2003], and PIs 
are not only substrates for P-gp [Profit et al. 1999; Washington et al. 1998; Lee et al. 
1998; Gutmann et al. 1999] but also for MRP, including both MRP1 and MRP2 
[Gutmann et al. 1999; Srinivas et al. 1998]. Previous in vitro study [Janneh et al. 2005] 
has shown that specific and non-specific inhibitors of P-gp, MRP1 and MRP2 
significantly increased the intracellular accumulation of saquinavir in human PBMCs. 
Furthermore, ritonavir (in combination with lopinavir) and rifampicin, which are 
frequently co-administered with efavirenz and lopinavir, have also been identified as the 
inhibitor and inducer of these energy-dependent drug efflux proteins, respectively. 
However, modulation effects of low-dose ritonavir (as a pharmacoenhancer) and 
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HIV-infected patients on intracellular accumulation of efavirenz and lopinavir are 
unknown. In this chapter, in vitro effects of several drug efflux protein inhibitors as well 
as ritonavir and rifampicin on the intracellular accumulation of efavirenz and lopinavir 
were demonstrated using healthy human PBMCs. 
 
The in vivo intracellular concentrations of various ARV drugs have been determined in 
adult Caucasian population [Chaillou et al. 2002; Colombo et al. 2006; Ford et al. 2004 a; 
Ford et al. 2004 b; Khoo et al. 2002; Ford et al. 2004 c; Almond et al. 2005 a; Almond et 
al. 2005 b; Crommentuyn et al. 2004; Colombo et al. 2004; Hoggard et al. 2002]. There 
is no information on intracellular concentrations in diseased paediatric population. In this 
chapter, efavirenz and lopinavir/ritonavir intracellular trough concentrations were 
evaluated in South African HIV-infected children. 
 
6.2 Methods 
6.2.1 In vitro ARV accumulation assay 
PBMCs (4 ×106 cells/mL) were incubated in RPMI growth medium at 37 ºC for half an 
hour in the absence and presence of drug efflux protein inhibitors: verapamil 
(non-specific inhibitor of drug efflux proteins; at 50 µM), furosemide (inhibitor of MRP1 
and MRP2; at 50 µM), cyclosporine A (inhibitor of P-gp; at 20 µM) and ritonavir 
(inhibitor of P-gp, MRP1 and MRP2; at 5 mg/L) and an inducer: rifampicin (inducer of 
P-gp; at 4 mg/L). Efavirenz and lopinavir in PBMCs were extracted and concentrations 
were determined by validated LC/MS/MS method. Data were expressed as cellular 
accumulation ratios (the ratio of efavirenz and lopinavir concentrations associated with 
cell pellet to medium, assuming a cell volume of 0.4 pL for each PBMC). More detailed 
procedures were described in Section 2.3. 
 
6.2.2 In vivo Intracellular ARV Drug Concentration Testing 
6.2.2.1 Efavirenz Children 
The extra group of TB/HIV co-infected children receiving standard doses of efavirenz as 
part of cART and rifampicin-based antitubercular treatment was recruited. The inclusion 
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dual treatment for at least 4 weeks had intracellular efavirenz concentrations evaluated at 
24 hours after the dose of efavirenz. Three of them had their efavirenz intracellular 
concentrations evaluated a second time at least 4 weeks after completing antitubercular 
treatment. 
 
6.2.2.2 Lopinavir-Ritonavir Children 
TB/HIV co-infected children receiving double dose Kaletra® (460/115 mg/m2) twice daily 
as part of cART and rifampicin-based antitubercular treatment were enrolled. Lopinavir 
and ritonavir intracellular concentrations were determined after children established on 
double dose Kaletra® for at least 4 weeks. Lopinavir and ritonavir intracellular 
concentrations were evaluated again in the same group of children at least 4 weeks after 
completing antitubercular treatment receiving twice daily standard dose of LPV/r 
(230/57.5 mg/m2; Kaletra®). Intracellular samples were collected before morning dose or 
12 hours after morning drug intake. 
 
All intracellular samples were collected from children recruited at the HIV Clinic, Red 
Cross Children’s Hospital in Cape Town. Institutional approvals of these two studies 
were granted by the research ethics committees of the University of Cape Town. 
Intracellular samples were stored at -20 ºC while awaiting quantification of 
concentrations. Efavirenz and lopinavir/ritonavir intracellular concentrations were 
extracted and determined by validated LC/MS/MS method (Section 2.4). 
 
6.2.3 Statistic Analysis 
Two-tailed t-test and One-way ANOVA followed by Bonferroni’s correction were used 




6.3.1 In vitro Effects of Drug Efflux Protein Inhibitors, Ritonavir and Rifampicin on 
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Wide inter-individual variability in the baseline accumulation of efavirenz and lopinavir 
(the control group, in the absence of P-gp modulators) were observed (Table 6.1). 
Verapamil (at 50 µM) significantly increased the efavirenz intracellular accumulation in 1 
of 3 PBMC samples compared to the efavirenz control (62.48± 11.04 vs. 41.89± 5.38; p= 
0.041). Whereas, significant effects were not found in the accumulation of lopinavir in 
any of these samples. The intracellular accumulation of efavirenz and lopinavir were not 
altered by the presence of cyclosporin A (at 20 µM) in 2 PBMC samples. In contrast, 
furosemide (at 50 µM) significantly increased efavirenz and lopinavir intracellular 
accumulation in PBMCs (p=0.018 and p= 0.016 for efavirenz and p= 0.034 for lopinavir). 
Ritonavir at the concentration of 5 mg/L had no significant effect on intracellular 
accumulation of efavirenz or lopinavir in 2 PBMC samples. The presence of rifampicin 
(at 4 mg/L) significantly increased efavirenz accumulation in 1 of 3 samples (p= 0.003) 
and a borderline increase was found on lopinavir accumulation in the same PBMC 
sample (p= 0.053). 
 
Table 6.1 Effects of drug efflux protein inhibitors/inducer on the intracellular 
accumulation of efavirenz and lopinavir. 
PBMC Samples 1 2 3 4 5 6 7 
Efavirenz Control 41.89± 5.38 41.92± 8.90 96.68± 10.57 83.78± 8.24 75.60± 18.27 57.42± 16.50 72.09± 11.07 
Verapamil 62.48± 11.04* 51.95± 11.45 92.85± 9.51 - - - - 
Furosemide - - - - - 87.00± 10.05* 90.00± 6.99* 
Cyclosporin A - - - 69.75± 4.00 79.88± 12.10 - - 
Ritonavir - - - 77.18± 15.45 86.18± 4.15 - - 
Rifampicin 70.88± 9.62* 48.45± 4.32 103.05± 10.37 - - - - 
PBMC Samples 1 2 3 4 5 6  
Lopinavir Control 190.65± 24.12 89.93± 22.42 86.63± 16.34 85.13± 4.92 89.34± 21.17 60.50± 3.66  
Verapamil 219.47± 21.25 85.13± 11.40 87.08± 14.52 - - -  
Furosemide - - - - - 76.77± 11.31*  
Cyclosporin A - - - 102.60± 25.86 71.81± 22.35 -  
Ritonavir - - - 72.53± 8.15 68.18± 16.01 -  
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* indicates statistically significant difference in intracellular accumulation of efavirenz 
and lopinavir compared to control. 
 
6.3.2 In vivo Intracellular Concentrations of Efavirenz, Lopinavir and Ritonavir 
Efavirenz intracellular concentrations were determined in 5 TB/HIV co-infected children 
during rifampicin-based antitubercular treatment. The isolation of PBMCs failed for 
patient 1 during antitubercular treatment due to haemolysis of blood sample. The median 
efavirenz intracellular/plasma concentration ratio for rest of the samples was 0.91 (IQR 
0.54, 1.19). Three children had efavirenz intracellular concentrations evaluated again 
after antitubercular treatment: Patient 2 had a higher efavirenz intracellular/plasma 
concentration ratio during antitubercular treatment compared to that after treatment (1.00 
and 0.61 for during and after antitubercular treatment, respectively), whereas efavirenz 
intracellular/plasma concentration ratio was increased after antitubercular treatment in 
patient 3 (0.79 vs. 0.27). The efavirenz intracellular concentration of patient 1 was not 
available during antitubercular treatment. The median efavirenz intracellular 
concentration for all 7 samples was 0.84 mg/L (IQR 0.38, 2.36). The median efavirenz 
intracellular/plasma concentration ratio was 0.81 (IQR 0.61, 1.38) (Table 6.2 and Figure 
6.1). 
 
Lopinavir and ritonavir intracellular concentrations were determined in 6 TB/HIV 
co-infected children receiving double dose LPV/r during antitubercular treatment. 
Patients 6 had both plasma and intracellular concentrations of lopinavir below LLOQ 
concentrations. Patient 7 had lopinavir intracellular concentration lower than LLOQ. 
Patients 6, 7 and 10 had ritonavir plasma concentrations below LLOQ, however, their 
ritonavir intracellular concentrations were within the quantification range. The 40% of 
LLOQ concentrations was adopted for samples with < LLOQ concentrations as described 
in Material and Method chapter. The median lopinavir and ritonavir intracellular 
concentrations were 0.20 mg/L (IQR 0.004, 0.30) and 0.11 mg/L (IQR 0.02, 0.22), 
respectively. The median lopinavir and ritonavir intracellular/plasma concentration ratios 
of all 6 samples were 0.22 (IQR 0.09, 0.31) and 4.17 (IQR 1.30, 7.33), respectively 
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lopinavir plasma concentrations observed in the majority of participants (data not shown). 
Lopinavir/ritonavir intracellular concentrations in children after antitubercular treatment 
were not available for evaluation of the effects of rifampicin on intracellular 
concentrations of PIs. 
 
Table 6.2 Intracellular efavirenz and lopinavir/ritonavir concentrations and 
intracellular/plasma concentration ratios in children with or without rifampicin-based 
antitubercular treatment. 
Patient On/off RIF 
Time after Dose 
(hours) 
Plasma (mg/L) Intracellular (mg/L) Ratio* 
Efavirenz      
1 On 24.00 0.24 No yield - 
1 Off 24.08 1.11 3.58 3.23 
2 On 24.00 0.43 0.43 1.00 
2 Off 24.01 0.54 0.33 0.61 
3 On 24.00 1.40 0.38 0.27 
3 Off 24.00 1.06 0.84 0.79 
4 On 24.00 2.91 2.36 0.81 
5 On 24.00 1.27 1.75 1.38 
Lopinavir      
6 On 12.00 0.02 0.004 0.20 
7 On 11.95 0.07 0.001 0.01 
8 On Pre-dose 3.22 0.30 0.09 
9 On Pre-dose 0.97 0.22 0.23 
10 On 12.00 0.18 0.18 1.00 
11 On Pre-dose 2.32 0.72 0.31 
Ritonavir      
6 On 12.00 0.01 0.02 2.00 
7 On 11.95 0.01 0.01 1.00 
8 On Pre-dose 0.10 0.13 1.30 
9 On Pre-dose 0.03 0.22 7.33 
10 On 12.00 0.01 0.09 9.00 
11 On Pre-dose 0.06 0.38 6.33 
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Figure 6.1 The intracellular/plasma concentration ratios for efavirenz, lopinavir and 




























6.4.1 In vitro Intracellular Accumulation of Efavirenz and Lopinavir in PBMC 
Samples 
Furosemide, a MRP1 and MRP2 inhibitor, significantly increased efavirenz and lopinavir 
accumulation in healthy human PBMC samples by 1.2- 1.5 fold, which was comparable 
with the average 1.9-fold increase on saquinavir accumulation in a previous study 
[Janneh et al. 2005]. Whereas, neither verapamil nor cyclosporin A had significant effects 
on efavirenz or lopinavir intracellular accumulation. Although ritonavir has been reported 
to be at least as good a P-gp inhibitor as cyclosporin A in renal proximal tubules isolated 
from teleost fish [Gutmann et al. 1999], it was found that the inhibitory effect of ritonavir 
on drug efflux proteins at the concentration reflecting its average plasma concentration in 
HIV-infected patients did not alter efavirenz or lopinavir accumulation in PBMC samples. 
Similar observation was reported by an in vivo study which showed that 
co-administration of ritonavir did not boost the median intracellular/plasma concentration 
ratios of saquinavir or indinavir [Khoo et al. 2002]. The reason for the failure of ritonavir 
to increase intracellular accumulation of PIs could be that the concentrations required for 
ritonavir inhibiting P-gp and MRP are much higher than those required for inhibition of 
HIV replication and than those used for boosting [Srinivas et al. 1998]. Therefore, the 
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presence of low-dose ritonavir. A study using P-gp-deficient mice concluded that 
ritonavir was a weak inhibitor of P-gp [Huisman et al. 2001], thus the improved 
bioavailability of PIs in combination with ritonavir may primarily result from CYP3A4 
inhibition. Despite being an inducer of P-gp, rifampicin increased the accumulation for 
both efavirenz and lopinavir to different extents in all 3 PBMC samples, suggesting the 
presence of rifampicin may compete with ARV drugs for protein binding, resulting in the 
increased concentrations of unbound ARV drugs and consequently more free drug is 
available for distribution into the PBMCs. 
 
6.4.2 In vivo Intracellular Concentrations of Efavirenz, Lopinavir and Ritonavir 
Although in vitro experiment could provide conceptual insights into intracellular 
localization properties of ARV drugs and the influences of concomitant drugs on cellular 
accumulation, factors such as age and disease states could alter the plasma protein 
content and therefore drug accumulation. In fact, an in vitro study has shown that HIV 
infection appeared to reduce intracellular accumulation of PIs in cells expressing efflux 
transporters [Jones et al. 2001]. It is important to determine the in vivo intracellular 
concentrations of ARV drugs in diseased population. 
 
This study in children showed the comparable median intracellular efavirenz 
plasma/intracellular concentration ratio with those observed by Rotger et al. and 
Colombo et al. (geometric mean reported) (0.81 vs. 0.9 and 0.71, respectively) [Rotger et 
al. 2005; Colombo et al. 2006], however, less than reported by Almond et al. (median 
0.81 range 0.27, 3.23 vs. median 1.3 range 0.7, 3.3) [Almond et al. 2005 a], suggesting 
that the factors such as age, population differences and disease states may contribute to 
the differences. Due to smaller samples size, the correlation between intracellular and 
plasma concentrations of efavirenz in this study was not as good as reported by Colombo 
et al. (slope= 0.90, R2= 0.38, p= 0.272 vs. slope= 0.69, R2= 0.58, p< 0.0001) [Colombo et 
al. 2006]. In chapter 3, we reported that sub-therapeutic efavirenz plasma concentrations 
were found in large proportion of African paediatric population, moreover, the cellular 
efavirenz exposure in children was similar or less than that in adults. For this reason, 
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efavirenz exposure and long-term treatment efficacy needs to be carried out. Larger 
sample size is needed to draw definite conclusion about the effect of concomitant 
rifampicin on efavirenz intracellular/plasma ratio. 
 
The intracellular accumulation of ritonavir was much higher than that of lopinavir when 
double dose LPV/r was given twice daily with concomitant rifampicin-based 
antitubercular treatment. In this study, lopinavir intracellular/plasma concentration ratios 
were lower than previously reported values (median 0.22 IQR 0.09, 0.31 vs. median 1.18 
IQR 0.74, 2.06 [Crommentuyn et al. 2004]; 1.55 IQR 0.67, 3.80 [Hoggard et al. 2002] 
and mean 0.65 standard error 0.12 [Colombo et al. 2004]). Furthermore, 
intracellular/plasma concentration ratios of lopinavir trough concentrations were much 
lower than those reported amongst adults with virological suppression after receiving 
LPV/r (400/100 mg twice daily) for 6 months (median 0.22 IQR 0.09, 0.31 vs. median 2.4 
IQR 1.6, 3.1), and all lopinavir trough concentrations were below the reported 
intracellular lopinavir Cmin efficacy threshold (8 mg/L) [Breilh et al. 2004]. However, the 
virological outcomes were not available as the study was terminated due to 
sub-therapeutic lopinavir plasma concentrations observed in the majority of children 
receiving double dose of LPV/r with concomitant antitubercular treatment. 
 
Ritonavir intracellular/plasma concentration ratios (median 4.17 IQR 1.30, 7.33) was 
comparable with values reported by Crommentuyn et al. and Hoggard et al. (median 4.59 
IQR 3.20, 7.70 and mean 5.28, respectively), and greater than reported by Colombo et al. 
(mean 0.94 standard error 0.18) [Colombo et al. 2004]. Factors such as age, population 
differences, disease status, dosing strategies and concomitant medications could 
contribute to the differences of the findings. Poor correlations were observed between 
intracellular and plasma concentrations for lopinavir and ritonavir (slope= 0.14, R2= 0.51, 
p= 0.112 and slope= 1.85, R2= 0.23, p= 0.330, respectively). 
 
In summary, intracellular accumulation is a dynamic process influenced by oral 
bioavailability, plasma protein binding, physiochemical properties, intracellular trapping 
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sample size; however it is difficult to recruit large numbers of paediatric patients for 
pharmacokinetic studies. Further investigations regarding P-gp expression on PBMCs 




















In this PhD project, the plasma, whole blood and intracellular concentrations of efavirenz, 
lopinavir and ritonavir were evaluated in HIV-infected African children with and without 
concomitant rifampicin-based antitubercular treatment. 
 
The main objectives of the project and their outcomes are summarized below. 
 
Objective 1: To develop and validate a simple and rapid efavirenz, lopinavir and 
ritonavir concentration testing methods requiring small volumes of plasma using 
LC/MS/MS. 
 
The LC/MS/MS methods were successfully developed and validated to simultaneously 
determine efavirenz, lopinavir and ritonavir concentrations in plasma. 
 
Objective 2: In African children receiving cART with and without tuberculosis, to 
evaluate the effect of concomitant rifampicin-based antitubercular treatment on efavirenz 
concentrations. 
 
It was found that efavirenz concentrations were not significantly different during and after 
antitubercular treatment, indicating rifampicin is not an important determinant of 
efavirenz concentrations in children. However, the study may be underpowered to detect a 
moderate reduction in efavirenz concentrations due to small sample size and large 
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antitubercular treatment on efavirenz concentrations. It is not possible to draw conclusions 
about the association between efavirenz concentrations and treatment outcomes in the 
study population as sample size was small and viral load information was not available for 
all participants at a standardized time point. However, as efavirenz concentrations were 
below the recommended therapeutic range in large proportion of children with or without 
concomitant rifampicin, findings raise concerns about the adequacy of current efavirenz 
dosing guidelines in children, and TDM is recommended to optimize individual dosing. 
 
Objective 3: In African children receiving cART with and without tuberculosis, to 
evaluate the lopinavir and ritonavir concentrations during rifampicin-based 
antitubercular treatment with an adjusted dose of lopinavir/ritonavir (lopinavir: ritonavir 
ratio of 1:1) in comparison to those after antitubercular treatment and in a group of 
controls. 
  
Large inter-individual viability was observed in lopinavir and ritonavir concentrations. 
This study showed that the addition of extra ritonavir to LPV/r (lopinavir: ritonavir ratio 
1:1) during rifampicin-based antitubercular treatment prevented significant reductions in 
the lopinavir key PK parameter, Cmin. The recommended minimum therapeutic 
concentration was achieved in the majority of children with and without antitubercular 
treatment. Therefore, in the context of the limited options available for young children 
with prior exposure to nevirapine, or maternal NNRTIs, LPV/r with additional ritonavir 
(lopinavir: ritonavir ratio 1:1) is an acceptable approach to treat children receiving 
concomitant rifampicin-based antitubercular treatment. However, due to the large 
inter-patient variability observed, TDM is recommended for this group of children. 
Although the adjusted dose of LPV/r was generally well tolerated in children, further 
investigation regarding the toxicity and efficacy of LPV/r with extra ritonavir and 
rifampicin-based antitubercular treatment is needed. 
 
Objective 4: To develop and validate the use of a DBS method to facilitate the 
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The LC/MS/MS methods were successfully developed and validated to simultaneously 
determine efavirenz, lopinavir and ritonavir concentrations in DBS samples. 
 
There were strong log/log linear correlations between plasma and DBS concentrations for 
efavirenz, lopinavir and ritonavir. However, co-variants such as HB concentrations and 
co-administration of rifampicin influenced DBS/plasma drug concentration ratios, 
indicating that these factors affect the drug distributions between the cellular blood 
component and plasma. All 3 drugs showed good stabilities in DBS samples. Overall, 
DBS is a simple and field-friendly method which can facilitate TDM and research studies 
in children. Further investigation regarding the effects of disease states and concomitant 
treatment on drug protein binding may provide explanations to the uneven drug 
distribution between blood cells and plasma. 
 
Objective 5: To determine intracellular efavirenz, lopinavir and ritonavir trough 
concentrations in HIV-infected children with and without concomitant rifampicin-based 
antitubercular treatment (in vivo). 
 
The LC/MS/MS methods for simultaneously determining intracellular concentrations of 
efavirenz, lopinavir and ritonavir were successfully developed and validated. 
 
This small pilot study is the first to evaluate the intracellular concentrations of ARV 
drugs in HIV-infected children. The intracellular/plasma concentration ratios observed 
(median 0.81, 0.22, 4.17 for efavirenz, lopinavir and ritonavir, respectively) were 
different to those reported in adults. Factors such as age, population differences, disease 
states, dosing strategies and concomitant medications might partly explain the differences. 
Future investigations regarding free drug concentrations and the expression levels of drug 
efflux proteins on lymphocytes could establish the relationship between total and free 
drug concentrations with intracellular drug exposure, plasma protein binding and 
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Objective 6: To evaluate the effects of rifampicin and ritonavir on efavirenz and 
lopinavir intracellular accumulation in human PBMCs (in vitro) 
 
It was found that ritonavir, an inhibitor of transmembrane drug efflux proteins, had no 
effect on lopinavir intracellular accumulation in the PBMCs. Rifampicin increased the 
accumulation for both efavirenz and lopinavir, suggesting that competition for protein 
binding may play an important role. A limitation of this study is that the expression level 
of each different type of drug efflux proteins on PBMCs, which could help to identify the 
specificity of ARV drugs to different types of drug efflux proteins, was not measured. 
 
In summary, this study added important value on optimizing ARV treatment in HIV 
infected children with concomitant antitubercular treatment, especially for whom living in 
high-burden countries with limited options of ARV and antitubercular drugs available. 
Future investigation regarding identification of the factors which could affect on 
intracellular ARV drug accumulation in order to improve the drug accumulation within 
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Study Dose (mg/kg) Cmin (mg/L) Cmax (mg/L) AUC (mg·h/L) CL/F (L/h/kg) % below Target* 
Starr et al. 1999 (n=50) (2 weeks) 
Median 8 years 
(range 3.8, 16.8) 
Mean 11.7 - - Mean 68.8 - 
22% (based on Cmin) 
44% (based on AUC) 
von Hentig et al. 2006 (n=11) 
4- 10 years 
10-15 
Mean 1.29 
(95% CI 0.89, 1.70) 
Mean 5.55 
(95% CI 3.95, 7.15) 
Mean 63.6 
(95% CI 44.2, 83.0) 
- 63.6% 
King et al. 2009 (n= 15) 
Median 13 years  
(range 10, 16) 
Median 10.7 
(range 3.4, 13.7) 
Median 0.77 
(range 0.2, 2.5) 
Median 3.57 mg/L 
(range 1.4, 7.6) 
Median 40.87 
(range 13.7, 86.2) 
Median 8.5 
(range 2.3, 22.9) 
53% (Cmin) 
14% (AUC) 
Hirt et al. 2009 (n= 48) 
Median 6.35 years  
(range 2.77, 14.7) 
Mean 14.4 Mean 1.64 Mean 3.71 Mean 65.2 Mean 0.21 19% (Cmin) 
Wintergerst et al. 2008 (n= 33) 
Median 8.2 years 
(range 2.1- 16.7) 
Median 13.3 
(range 9.7, 22.5) 
MDI (at first sampling) 
2/3 sampled between 8- 12 hours 
Median 2.8 (range 0.13, 11.6) mg/L 
- 
Median 0.30 
(range 0.07, 1.0) 
8.8% (MDI) 
Puthanakit et al. 2009 (n= 63) 
Median 12.3 years 
(range 3.1- 18.7) 
Mean± SD 
12.0± 1.6 
Sample time mean(± SD) 14.8± 0.8 hours 
MDI Mean± SD 3.14± 3.31 mg/L 
- - 13% (MDI) 
SD= standard deviation; Cmin- trough concentration; AUC- area under the curve; MDI- mid-dosing interval; CL/F- Apparent Elimination Clearance 













Table A.2 The previously reported lopinavir PK parameters (in children). 
 
 
Lopinavir PK Measures 
Study Dose (mg/m
2
) Cmin (mg/L) Cmax (mg/L) Tmax (hours) AUC (mg·h/L) CL/F (L/h/kg) Half-life (hours) 
Sáez-Llorens et al. 2003  













Verweel et al. 2007  
(n=23) 
Median 5.6 years  




(IQR 0.67, 5.48) 
9.33± 3.27 
Median 10.6 




(IQR 46.6, 106.4) 
Median 0.11 
(IQR 0.08, 0.24) 
6.59± 4.19 
Median 5.73 
(IQR 3.04, 8.96) 
Chadwick et al. 2008  
(n= 18) 
Median 3.4 months  
(range 1.6, 5.9) 
300/75 Mean 2.0 Mean 9.4 - 
Mean 74.5 
Median 67.52 
(range 23.66, 164.04) 
Median 0.187 
(range 0.073, 0.610) 
Median 3.68 
(range 1.2, 13.11) 
Chadwick et al. 2009  
(n= 9) 
Median 5.7 weeks 
(range 3.6, 5.9) 
300/75 Mean 1.4 
Mean 5.17 
Median 4.76 




(range 27.9, 62.6) 
Mean 0.43 
Median 0.37 
(range 0.15, 0.75) 
Mean 3.67 
Median 3.51 
(range 2.06, 5.80) 
 















Table A.3 The previously reported intracellular/plasma concentration ratios for efavirenz, 
lopinavir and ritonavir. 
 
 
Intracellular/plasma Concentration Ratios 
Study Efavirenz 
Rotger et al. 2005 Median 0.9 
Colombo et al. 2006 
(n= 62) 
Geometric mean 0.69 
(geometric CV 101) 
Almond et al. 2005 a 
(n= 10) 
Median 1.3 
(range 0.7- 3.3) 
 Lopinavir Ritonavir 




(IQR 0.74, 2.06) 
Median 4.59 
(IQR 3.20, 7.70) 




(range 0.67, 3.80) 
Median 5.28 




(standard error 0.12) 
Mean 0.94 
(standard error 0.18) 
virological success vs. failure (1 month) 
Median 3.2 (IQR 2.6, 3.8) vs. 2.3 (IQR 1.9, 2.8) 
Breilh et al. 2004 
(n= 38) 
LPV/RTV combination virological success vs. failure (6 month) 
Median 2.4 (IQR 1.6, 3.1) vs. 1.4 (IQR 1.3, 1.7) 
- 
Khoo et al. 2002 
(n= 6) 
RTV single agent 
- 
Median 1.00 
(range 0.60, 2.28) 
CV- Coefficient of variation; IQR- Interquartile range; LPV- Lopinavir; RTV- Ritonavir 
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